Alzheimer’s Disease

Edited by Montasir Elahi

This Edited Volume of Alzheimer’s Disease is a collection of reviewed and relevant research chapters, offering a comprehensive overview of recent developments in the field. The book comprises single chapters authored by various researchers and edited by an expert in the field, working on Alzheimer’s disease and dementia with cutting-edge technology. All chapters are complete in themselves but united under a common research study topic. This publication aims at providing a thorough overview of the latest research efforts by international authors in this research area and opening new possible research paths for further novel developments.

Published in London, UK

© 2022 IntechOpen

ISBN 978-1-83969-343-4
We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

6,100+ Open access books available
149,000+ International authors and editors
185M+ Downloads

156 Countries delivered to
Top 1% Our authors are among the
most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index (BKCI)
in Web of Science Core Collection™

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Montasir Elahi currently works as a Research Associate at the University of Maryland, Baltimore, United States of America. He obtained his Bachelor’s Degree from the University of Dhaka (Biochemistry and Molecular Biology) in 2003, a Master’s Degree from the University of Dhaka in 2004, and a Ph.D. from Tokyo University of Agriculture and Technology (Biotechnology and Life Sciences) in 2014. From 2008 to 2012 he received a Japanese Govt MEXT Fellowship for pursuing doctoral studies. From 2007 to 2008 he worked at the Research Office, International Center for Diarrhoeal Disease Research, Bangladesh. From 2014 to 2016 he was a Post-doctoral fellow at Juntendo University School of Medicine and from 2016 to 2021 he was a Project Assistant Professor at the Department of Diagnosis, Prevention and Treatment of Dementia and Department of Neurology, Juntendo University School of Medicine. Dr. Elahi performs research in Neuroscience, Protein science and Structural biology.
Contents

Preface XIII

Chapter 1
Perspective Chapter: Alzheimer - A Complex Genetic Background
by Marco Calabrò and Concetta Crisafulli 1

Chapter 2
An Innovative Framework for Integrative Rehabilitation in Dementia
by Valentin Bragin and Ilya Bragin 35

Chapter 3
Alzheimer’s Disease: An Insightful Review on the Future Trends of the Effective Therapeutics
by Afreen Hashmi, Vivek Srivastava, Syed Abul Kalam and Devesh Kumar Mishra 57

Chapter 4
MicroRNAs as Future Treatment Tools and Diagnostic Biomarkers in Alzheimer’s Disease
by Heena Chauhan, Pawan Gupta and Bhagawati Saxena 81

Chapter 5
Perspective Chapter: Exercise-Eating Pattern and Social Inclusion (EES) is an Effective Modulator of Pathophysiological Hallmarks of Alzheimer’s Disease
by Afroza Sultana and Md Alauddin 105
Preface

This Edited Volume is a collection of reviewed and relevant research chapters concerning the recent developments in Alzheimer’s disease. The book includes scholarly contributions by various authors and edited by an expert in the field, working on Alzheimer’s disease and dementia with cutting-edge technology. Each contribution comes as a separate chapter complete in itself but directly related to the book’s topics and objectives.

The book is divided in 5 chapters. The target audience comprises scholars and specialists in the field.

Montasir Elahi
University of Maryland,
Baltimore, United States of America
Chapter 1

Perspective Chapter: Alzheimer - A Complex Genetic Background

Marco Calabrò and Concetta Crisafulli

Abstract

Alzheimer is a complex, multifactorial disease with an ever increasing impact in modern medicine. Research in this area has revealed a lot about the biological and environmental underpinnings of this disease, especially its correlation with B-Amyloid and Tau related mechanics; however, the precise biological pathways behind the disease are yet to be discovered. Recent studies evidenced how several mechanisms, including neuroinflammation, oxidative stress, autophagy failure and energy production impairments in the brain, —— have been proposed to contribute to this pathology. In this section we will focus on the role of these molecular pathways and their potential link with Alzheimer Disease.

Keywords: molecular pathways, genetics, Alzheimer

1. Introduction

Alzheimer’s disease (AD, MIM: 104300) is the most common neurodegenerative disorder worldwide, accounting for 60% up to 80% of Dementia causes [1]. This disease is one of the fastest rising diseases among the 50 leading causes affecting of life expectancy [2]; according to this trend, the number of AD subjects is destined to rise over 150 million by 2050 [3, 4].

AD worsen with time and as it progresses, patients usually develop short-term to long-term memory loss, accompanied by confusion, irritability and aggression, [5], followed by language impairments and mood swings [6].

Despite its prominence in modern society and the thriving research around it, a lot of its intricate pathophysiology is yet to be discovered. Furthermore, grade and type of symptoms may vary greatly from person to person [7], adding to the complexity of AD. Nevertheless, post mortem observations on AD subjects’ Central Nervous System (CNS) evidenced some central histopathological features, mainly focused on amyloid beta (Aβ) plaques and neurofibrillary tangles (NFTs) [8–11].

Aβ plaques are the extracellular deposit of Aβ, which are produced by the cleavage of amyloid precursor protein (APP) [12], while the NFTs consist of abnormal filaments of hyper-phosphorylated Tau by GSK-3β [13]. They are thought to have a significant impact in memory and cognitive function, by triggering synaptic loss or dysfunction and neuronal death [14].

Interestingly, although not all of the causes have been located, AD cases seemingly converge to these hallmarks, providing a steady starting point for trying to understand the biological processes behind this disease.
1.1 Genetics

Indeed, among the cases of AD genetic studies individuated a form, known as Familial AD (FAD), that runs in families and is transmitted with an autosomal dominant model [15]. FAD is the best described type of AD: it is associated with mutations in three major genes: APP (chromosome 21), PSEN1 (chromosome 14) and PSEN2 (chromosome 1) [16]. Alterations within these genes affect amyloid

<table>
<thead>
<tr>
<th>Familial AD (FAD)</th>
<th>OMIM ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>An Alzheimer’s disease that has_material_basis_in mutation in the gene encoding the amyloid precursor protein on chromosome 21q.</td>
<td>OMIM:104300</td>
</tr>
<tr>
<td>An Alzheimer’s disease that has_material_basis_in mutation in the presenilin-1 gene (PSEN1) on chromosome 14q24.</td>
<td>OMIM:607822</td>
</tr>
<tr>
<td>An Alzheimer’s disease that has_material_basis_in a mutation in the presenilin-2 gene (PSEN2) on chromosome 1q22.</td>
<td>OMIM:606889</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sporadic AD (SAD)</th>
<th>OMIM ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>An Alzheimer’s disease that is characterized by an association of the apolipoprotein E E4 allele.</td>
<td>OMIM:104310</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 12p11.23-q13.12.</td>
<td>OMIM:602096</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 10q24.</td>
<td>OMIM:605526</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 10p13.</td>
<td>OMIM:606187</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 20p12.2-q11.21.</td>
<td>OMIM:607116</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 7p36.</td>
<td>OMIM:608907</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 6p22.1.</td>
<td>OMIM:609636</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 8p12-q22.</td>
<td>OMIM:609790</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 1q21.</td>
<td>OMIM:611073</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 3q22-q24.</td>
<td>OMIM:611152</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 1q25.</td>
<td>OMIM:611154</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with variation in the region 3p12-q22.</td>
<td>OMIM:604154</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with a risk allele in the PCDH11X gene on chromosome Xq21.3.</td>
<td>OMIM:300756</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by an associated with mutations in the gene TREM2.</td>
<td>OMIM:615080</td>
</tr>
<tr>
<td>An Alzheimer’s disease that has_material_basis_in a mutation in the ADAM10 gene on chromosome 15q21.</td>
<td>OMIM:615590</td>
</tr>
<tr>
<td>An Alzheimer’s disease that is characterized by associated variants of the gene PLD3.</td>
<td>OMIM:615711</td>
</tr>
</tbody>
</table>

Table 1. Alzheimer sub-types according to genetics. [30407550]
cleavage, directly promoting plaques formation. Several studies demonstrated that alterations in APP or PSEN1 genes are guaranteed to cause AD, while PSEN2 mutations have a 95 percent chance of causing the disease [17]. Unfortunately, only up to 5% of all AD cases are of this type [18].

Other cases usually go under the name of sporadic AD (SAD) which encloses the largest part of AD cases. SAD cases have a more cryptic and heterogenic genetic background [18]: More than 500 candidate genes were correlated with SAD [15, 19, 20]. Of them, inherited polymorphic APOe (chromosome 19) E4 allele is the major risk factor. APOe is the gene encoding for the Apolipoprotein E, whose function is to bind lipids and sterols and transport them through the lymphatic and circulatory systems. APOe4 is thought to produce a more instable form and is related to the formation of neurofibrillary tangles [21, 22] and amyloid clearance processes [23, 24], through a still not well understood mechanism.

1.1.1 Apolipoprotein E (APOe)

APOe is in charge of cholesterol transport in the brain [25, 26]. As said before, the e4 isoform of this protein is associated to increased AD-risk [27–30]. The fine molecular mechanisms behind the risk increase operated by APOe4 are not completely characterized, however data obtained from cell cultures evidenced how APOe4 promotes oxidative stress and the generation of neurotoxic fragments which impairs mitochondrial activity [31–33]. In particular, APOe4 isoform seems correlated to an increased α-synuclein (αSyn) accumulation accompanied with synaptic loss, lipid droplet accumulation and dysregulation of intracellular organelles [34]. αSyn is a presynaptic membrane-bound protein abundantly expressed in the brain and is involved in synaptic signaling and membrane trafficking [34]. Further, over other 50 loci/genes have been implicated in SAD [15, 35, 36], underlining AD’s complexity and the possibility of it being triggered by different alterations. Indeed, up to date, literature (OMIM and GO) reports 19 different AD subtypes based on different associated loci. Table 1 reports a summary of such subtypes.

2. The pathways of Alzheimer disease

The number of genetic factors described is important contributors to AD. However, neither APOE4 nor the other correlated genes are entirely sufficient to explain (and promote) the totality of AD cases [37].

In such a complex environment represented by multicellular organisms a gene and its product/s is not a stand-alone entity. Each protein interacts with and influences many other elements in a synergic orchestra that regulates an organism.

As such, a single alteration propagates (indirectly) its effects to its interactors following pathways and molecular cascades.

Indeed, rather than single genes, a better approach would be investigating AD as an event related to alterations affecting entire biological pathways. Within this chapter, we will focus on molecular cascades potentially involved in AD. A plethora of mechanisms, including neuroinflammation [38], oxidative stress [39, 40], defects in mitochondrial dynamics and function [41], synaptic and cholinergic malfunctions [42], cholesterol and fatty acid metabolism as well as glucose energetic pathways impairments in the brain [43, 44], autophagy failure [45], apoptosis with multiple cell signaling cascades [42, 46] and other less studied mechanisms have been proposed to contribute to AD. It should be stressed that while they are discussed separately, these pathways are all interlinked and changes in one may very well result in changes in the others.
2.1 Hallmarks of AD: Aβ and tau related pathways

Aβ is a 4 kDa fragment derived by two subsequent proteolytic cleavages of amyloid precursor protein (APP) by β and γ secretases [47]. As evidenced in studies focused on FAD, genetic alterations of APP, PSEN1 and PSEN2 may negatively influence cleavage promoting Aβ production. Interestingly, contrary to what was once believed, low concentrations of Aβ are seemingly needed to short and long term memory processes [48, 49], and Aβ homeostasis is a lot more regulated than once expected, consisting of highly conserved feedback loops and interactions between multiple processes [50].

Potentially risk genes may be found among the ones regulating the biological networks involved in Aβ expression and APP cleavage (including APP, PSEN1, PSEN2, ADAM10, BACE1), its localization and transport (like APOE, CLU, SORL1) and its degradation and clearance (including ABCA7, BIN1, CD2AP, CD33, PICALM, PTK2B and RIN3) [50, 51]. Interestingly, the same elements are interlinked with other important pathways (see later in the text). Aβ accumulation also impairs the structure and function of microglia, astrocytes, and vascular endothelial cells of the brain [52, 53].

The neurotoxic function of Aβ is linked to Tau, a microtubule-associated protein that provides structural assembly and stability of cytoskeletons [54, 55]. The expression of tau is critical during Aβ-mediated synaptic processes where Aβ peptides target phosphorylation-based pathways [55] which hyper-phosphorylate Tau protein through glycogen synthase kinase 3 beta (GSK-3β) and other kinases activated by Aβ peptides [56], and promote their release from microtubules. The removal of Tau from microtubules favors the formation of NFTs composed by aberrantly folded form of hyper-phosphorylated tau and alter the structure of neuritis, giving rise to synaptic malfunction and neuronal death [52].

2.2 Oxidative stress

Oxidative stress (OS) has been widely recognized as a prodromal factor associated to AD [57]. According to the current knowledge, increased OS is a sign often observed in the brain of early-stage AD subjects [58]. In particular, OS may act as indicator of changes within the brain. Regarding its correlation with Aβ accumulation, it is known that Aβ is both a cause and the result of OS, as Aβ structure facilitates OS induction [59] and represents a source of radical oxygen and nitrogen species (ROS, RNS) [57]. Through proteic mediators, including NOX, TGF-β, NF-κB and NRF2 genes’ products [60], Aβ increases OS levels and triggers several molecular events that are strictly linked with AD development [61]: OS promotes Tau phosphorylation [62] and also exerts its effect on the choline recycling from the synapse processes, leading to ACh deficiency [63]. It also causes deficit in the energy metabolism (through impairment of mitochondria function and Blood Brain Barrier (BBB) permeability) and leads to apoptosis and then neurodegeneration [64–66]. Of particular relevance, excessive ROS inevitably lead to lipid peroxidation [67], which has been proposed as early biomarker of AD [68]. OS cause damage to all biomolecules. In particular, unsaturated lipids are very sensitive to their action. It should be noted that the brain gray matter and white matter are both very rich in polyunsaturated fatty acids (e.g. docosahexanoic acid, adreinic acid which are brain tissue specific) [69], making the nervous system very sensible to lipid peroxidation [69]. The action of OS in AD through lipid peroxidation is supported by histological evidences showing the co-localization of lipid peroxidation metabolites and Aβ plaques in the brain [70]. Further, it was demonstrated (in culture studies)
that the lipids usually found in AD brain lesions produce neurotoxic effects in presence of increased OS levels [71]. Indeed, the chemical reactions following lipid peroxidation often results in the production of isoprostanes and malondialdehyde, which causes DNA damage and toxic stress in cells [72]. Interestingly, the products of lipids peroxidation can be found in bio-fluids such as blood and urines, supporting their potential for diagnosis of AD. As AD potential biomarkers, some of these metabolites were investigated in literature [73]. However, their effective use in clinic is still debated as they showed some promising but contradictory results [68].

2.3 Inflammation

Inflammation is a physiological acute event, which is essential to defend the body against toxins and pathogens and for tissue repair. However, if inflammation becomes chronic, it causes detrimental effects with severe consequences. Among the processes involved with AD, the persistent over-activation of the inflammatory cascade represents one of the main biological mechanisms through which AD progresses: indeed, neuroinflammation is not typically associated to AD onset, but it plays a key role in increasing the severity of the disease by exacerbating Aβ and Tau nefarious effects [74–76].

The main players behind cytokines production are the non-neuronal cells that populate the brain, such as microglia, astrocytes, and oligodendrocytes [77–79]. Literature data evidenced that Aβ up-regulates cytokines production by these cells. Further, the presence of Aβ stimulate microglia toward the chronicization of pro-inflammatory state by activating the NF-κB cascade [80–82] or promoting Aβ interaction with FPR2 [83]. Under such conditions, microglia generates a wide range of cytotoxic factors, including interleukins, TNF-α, superoxide, nitric oxide, ROS, prostaglandins and Cathepsin B, which damage extracellular matrix and cause neuronal dysfunction [75, 84]. The increase of cytokines triggers several potentially harmful effects: it induces mitochondrial stress in neurons, either directly or indirectly, including via Aβ signaling. It also increases OS [85, 86] and Blood–Brain Barrier (BBB) permeability which likely influence AD progression [87].

Similar to microglia, astrocytes also produce and/or release an array of inflammatory mediators. Activated or “reactive” astrocytes can be roughly classified in two groups: the “A1” neurotoxic phenotype and the “A2” neuroprotective phenotype based on distinct transcriptional profiles [88]. The A1 group is likely involved with AD through mechanisms similar to microglia.

From a molecular point of view, cytokines like IL-1 and TNF-α promote Aβ production by up-regulating APP and the amyloidogenic secretases [81, 89], while IL-6 and IL-18 promote Tau hyper-phosphorylation [90, 91].

Ultimately, a cycle is established in which inflammation increases Aβ production (and triggers other negative processes increasing protein accumulation and OS), which in turn stimulate microglia to maintain its pro-inflammatory state. The uncontrolled cytokines production then causes neuronal death [38] as it damages synapses (please refer to Section 2.4), myelin sheaths and axons, promote complement-mediated damage and/or triggers apoptotic or necroptotic mechanisms [92]. This link between AD and microglia is also supported by Genome wide association studies, which evidenced how several genes (TREM2, CLU, CR1, EPHA1, ABCA7, MS4A4A/MS4A6E, CD33, CD2AP) related with an increased AD risk regulate glial inflammatory reaction [75]. Additionally, it has been observed that astrocyte-based inflammatory cascade could recruit peripheral macrophages, white blood cells, and lymphocytes that infiltrate brain parenchyma thanks to BBB increased permeability and vascular alterations [93].
2.4 Neurodevelopment and neurotransmission associated processes

Neurodevelopmental/Neuroplasticity and Neurotransmission related pathways are likely associated with AD development and in particular with its cognitive symptoms [94]. Physiologically, these processes consist in the proliferation, differentiation and maturation of neural stem cells (NSC) and the modulation of their interactions through synapse- and neurotransmission-related processes.

Regarding neurodevelopment processes, it has been observed that the synaptic pruning pathway becomes aberrantly up-regulated in the first stages of AD. This aberrant activation, which leads to synaptic loss [95], seems to be triggered by Aβ, through PANX1, ryanodine receptor (RyR) function [96, 97] other than several inflammatory signals [98].

PANX1 is a protein involved in the modulation of neurotransmission, neurogenesis and synaptic plasticity [99]. An increase of this protein under inflammatory conditions contributes to neuronal death [100].

RyR is Ca2+ channel which modulates different processes including neuronal development and plasticity [101].

The anomalous RyR channel function is triggered by Aβ and OS through Ca2+ increased concentrations [96] and are interlinked to mitochondrial and NOX2-mediated ROS generation [102] and glial activation [103].

Regarding the inflammatory elements, it has been observed that many cytokines directly interact with receptors located on neuronal membranes. Here they activate or modulate pathways involved in synaptic function and plasticity (e.g. p38 MAPK and NFκB pathways). Further, synapse function and stability are also heavily regulated by microglia and astrocytes. In particular, the former is seemingly implicated in pruning mechanics [95], while the latter appear to have an heavy involvement in regulating synapse formation, stability, and turnover [104]. Astrocytes physically wrap synapses. The synapse/astrocyte interface is fairly active as astrocytes release numerous proteins capable of modulating synaptic function, sprouting and remodeling.

Regarding neurotransmission, several reports have indicated a significant reduction of Serotonin (5-HT) [105], Dopamine (DA) [106] and Norepinephrine (NE) [107] levels as well as their receptors in AD brain. In AD, loss of 5-HT results in depression, anxiety and agitation [108], dysregulation of DA release leads to reward-mediated memory formation deficits [109] and low level of NE impairs spatial memory function [110]. Glutamatergic and cholinergic abnormalities in particular, were pointed as one of the principal causes of cognitive deterioration in AD.

2.4.1 Cholinergic neurotransmission

The cholinergic system regulates attention processing [111], cognition [111], memory function and behavior via the release of the neurotransmitter acetylcholine (ACh) [112].

Several studies evidenced how ACh production and reuptake are impaired in AD brains [113]. Further, accumulation of intraneuronal Aβ degenerates basal forebrain cholinergic neurons and reduces ACh levels [114], which in turn leads to memory deficits [115]. A potential candidate through which Aβ exerts its effect is α7nAChRs. Studies on α7nAChRs KO models evidenced how the lack of this receptor could induce AD-like pathology, including Aβ increase. In addition, its depletion is linked to an increased age-dependent expression of phosphorylated Tau [116, 117].

About the mechanisms underlying α7nAChR regulation of Aβ production, it seems that physiologically this receptor activations shifts APP processing toward
the non-amyloidogenic pathway [118], enhancing the production of the neuro-
protective APPα (soluble form) which is able to counteract Aβ neurotoxicity [119].
Interestingly, α7nAChRs mediate the intake of pre-synaptic Ca2+ levels during
neuronal activity, indirectly modulating all biological processes dependent on this
ion, glutamate release, synaptic transmission, and cognitive function [120]. When
α7nAChRs is reduced, a negative feedback mechanism is triggered which increase
Aβ production with the aim of maintaining Ca2+ influx in the cells [121]. Aβ in
turn, further decrease its expression. This reduction ultimately exerts its effect on
the N-methyl-D-aspartate receptor (NMDAR), which is removed from membrane,
and on nicotinic and MAPK signaling, resulting in the development of cognitive
deficits [122].

2.4.2 Glutamatergic neurotransmission

The most common excitatory neurotransmitter, glutamate, and its receptors
are required for neuronal cell differentiation, migration, survival, and synaptic
plasticity. There are two types of glutamate receptors: ionotropic glutamate recep-
tors (iGluRs), such as N-methyl-D-aspartate (NMDA), α-Amino-3-idrossi-5-
Metil-4-isossazol-Propionic Acid (AMPA) and Kainate receptors; and metabotropic
glutamate receptors (mGluRs).

Over-activation of these receptors causes neuronal excitotoxicity as well as
neuronal death, and this is thought to be one of the mechanism causing neu-
rodegeneration in AD [123]. Indeed, in patients with AD, available evidence
points to a disruption in the glutamatergic neurotransmission cycle at the
point of glial cell reuptake of free glutamate from the synapse: Aβ can interfere
with glutamate receptors and transporters [96]. The binding of such receptors
triggers neuronal susceptibility to glutamate excitotoxicity, dyshomeostasis and
defective plasticity [124]. The biological mechanism is still not well understood,
but likely needs the function of a tyrosine-protein kinase, Fyn, which alter
NMDARs function through phosphorylation [125]. Interestingly, Astrocytes
may also play a role in the impaired glutamate clearance from the synaptic cleft.
As said before, astrocytes wrap synapses. In the synaptic interface, these cells
present a high concentration of excitatory amino acid transporters (EAATs),
including EAAT1 and EAAT2. Physiologically, over 80% of extracellular gluta-
mate is taken by astrocytes through these transportes [126]. It has been observed
that Aβ peptides and pro-inflammatory elements down regulate the expression
of EAATs, impairing glutamate clearance [127]. As such, free glutamate accu-
mulates out of synapses while the vesicular glutamate uptake is reduced. The
consequence of this condition is a chronic low-level activation of glutamatergic
receptors on postsynaptic neurons and reduced sensibility to glutamate during
neuronal firing (due to the low concentration of the neurotransmitter within
vesicles) [128], leading to suboptimal neurotransmission and impairment of
long-term potentiation (LTP) [128].

2.5 Energy metabolism

Energy is of high importance to maintain the physiological function of the
brain. Processes related to energy production (Glucose intake, ATP production)
are disrupted in AD brains [129]: Indeed, several brain areas in AD patients show a
significant decrease of glucose metabolism [130]. Additionally, the first AD-related
intracellular lesions usually develop in neurons with a higher energy consumption
[131] and often involve enzymes related to tricarboxylic acid cycle, which lead
neurons to a hypo-metabolic state [63].
Interestingly, an excess of an important energy substrate, glucose, may also lead to the exacerbation of AD symptomatology. A high glucose concentration is also the main characteristic of diabetes. Other than being a risk factor for the development of diabetic complications, it seems to play a role in the development of AD cognitive symptoms [132]. Indeed, high levels of glucose are harmful for the brain, as they lead to Aβ accumulation on brain lesions. It also exacerbates OS and promotes neuroinflammation [133, 134], with the consequences already described in the previous sections. Glucose levels are affected by numerous elements, such as pro-inflammatory cytokines [135, 136]. However, the main control is exerted by the antagonistic function of insulin and glucagon. Insulin signaling has been the focus of multiple AD studies [137–139] were it was shown that both Aβ deposition and tau hyperphosphorylation are correlated with the impairment of Insulin signaling cascade [140, 141], and insulin resistance in particular. According to these observations, insulin resistance is a feature of both type 2 diabetes mellitus (T2DM) and AD, supporting a biological overlapping between the two pathologies. As said before, the high glucose condition increases Aβ production. On a molecular level this increase is linked to the inhibition of APP degradation pathways [142]. Chronic hyperinsulinemia in brain also leads to cognitive dysfunctions [143], Insulin receptor is present in hippocampus [144], the main area responsible for memory. A chronic exposition to insulin favors a resistance mechanism, making neurons less responsive to this hormone. Further, Aβ can interact with insulin receptors causing their internalization and thus inhibiting their function [145]. Additionally, Aβ seizing insulin receptor, increases insulin levels in the brain micro-environment, which in turn promote inflammation increasing TNFα, interleukin 1β and 6 (IL1β and IL6) [146]. Through a still not completely understood mechanic, the alteration of insulin signaling (or an increased resistance to insulin) ultimately triggers neuroinflammation and neurodegeneration, increasing Aβ concentrations and Tau hyper-phosphorylation [145, 147].

### 2.6 Autophagy impairments

Autophagy is an intracellular process mediated by vesicles and lysosomes that consists of several sequential steps which ultimately lead to the degradation of damaged/misfolded proteins and dysfunctional organelles, thereby sustaining cellular homeostasis [148]. Physiologically, this process is especially important for neuronal and glial cells health [149, 150]. Although it is still not clear whether dysfunction of autophagy is the cause or result of AD [151], it has been observed that the dysregulation of autophagy may occur in early stage of the disease. In particular, this process is believed to be a major pathway for Aβ clearance/accumulation [152] and is also involved in the pathological mechanisms of neurodegeneration [149, 150]. Studies on animal models also reported that restoring the physiological autophagosomes clearance ameliorate/prevents AD cognitive symptoms [153]. Studies on AD brains revealed a significantly higher presence of autophagosomal and pre-lysosomal vacuoles in neuronal dendrites and axons [154–156]. These vacuoles were shown to be enriched in APP, γ-secretase components, PSEN1 and nicastrin, which are required to generate Aβ [157, 158]. According to the autophagic hypothesis, the block of autophagy and the consequent accumulation of autophagosomes trigger neuronal degeneration [156] and leads to the release of these vesicles...
in the extracellular space where they form the characteristic AD plaques [159, 160]. Autophagy is also essential for Tau clearance [161]. Usually, Tau is transported in vacuole for degradation, however certain mutations of Tau, cause the block of this protein in the membrane of lysosome. The accumulation in the membrane impairs and disrupts lysosomal enzymes function and structure, which ultimately lead to the release of lysosomal enzymes in the cytoplasm [161].

Recent studies have proven that autophagy could be influenced by diverse factors, such as Aβ [162] and OS [163]. In addition, ApoE4 and Aβ influence of lysosomal membranes stability [164].

From a biological point of view, autophagy is mainly regulated according to the physiological condition of cells through several elements:

*ATG7* is a key gene regulating autophagy process [150]. It is involved in degradation of tau [165] and mediates the transport of Aβ peptides [166]. Alterations of its function have been correlated with AD [167].

Beclin 1 (*BECN1/ATG6*) protein mediates the initiation of autophagy [150]. BECN1 is involved in the pathophysiology of AD. The expression of BECN1 is decreased in brains of AD patients when compared with healthy individuals [168]. Decreasing of Becn1 expression leads to increased levels of Aβ [168] and also increases microglia inflammatory response [169].

The down-regulation of this protein is believed to be caused by caspase-3 up-regulation [170]. Further, BCL2 Apoptosis Regulator (BCL2) is an anti-apoptotic factor that regulate autophagy through BECN1 [171]. The overexpression of Bcl2 has protective effects against Aβ-driven neuronal death [170]. The overexpression of Bcl2 affects also tau processing, reducing the number of NFTs [170].

Cyclin Dependent Kinase 5 (CDK5) is an autophagy-regulating kinase [150], which influences the metabolism and effects of Aβ. CDK5 likely act through regulation of β-secretase, which is a crucial enzyme involved in APP metabolism [172]. This kinase also mediates Aβ peptide-induced dendritic spine loss [173], providing a pathway linking Aβ with cognitive dysfunction. Similarly, CDK5 is similarly involved in tau phosphorylation [174], although it seems to not be sufficient to trigger NFT formation [174].

Clusterin (*CLU/APOJ*) is a chaperone protein implicated in autophagosomes biogenesis via interaction with ATG8E (MAP1LC3A) [150]. According to meta-analyses data on AD subjects, this protein is one of the top AD candidate genes [37, 175, 176]. Its alterations have been suggested to affect neuron connectivity in several brain regions [177, 178]. Physiologically, CLU interacts with Aβ, preventing its aggregation [179, 180].

Cathepsin D (*CTSD*) is a lysosomal protease [150] involved in APP and Aβ degradation [181]. Its role and correlation in AD is still under debate as literature produced controversial results [182–185].

Alpha-Synuclein (*SNCA/PARK1/NACP*) is another protein found to be associated with AD risk [150]. SNCA is an important component of Aβ plaques [186] and can influence the expression of/be regulated by Aβ peptides [187, 188]. Similarly, to interaction of SNCA with Aβ peptides, SNCA and tau also induce each other fibrilization [189]. SNCA binds, phosphorylates, and inhibits microtubule assembly activity of tau [190].

**PINK1 and PRKN genes products** are important elements behind autophagosome-mediated mitochondrial degradation [191]. In AD, high levels of Aβ inhibit the expression of those proteins, leading to increased dysfunctional lysosomes and neurodegeneration [192, 193].

**Ubiquilin 1 (UBQLN1)** is involved in autophagosome–lysosome fusion [150], likely through ATG8E (MAP1LC3A) [194]. Meta-analyses studies correlate *UBQLN1* with an increased risk for AD [195, 196]. It has been observed that the
expression of UBQLN1 is reduced in AD patients [197, 198]. This decrease, in turn, up-regulates APP processing [198].

Ubiquitin C-Terminal Hydrolase L1 (UCHL1) influences autophagy by interaction with LAMP2 which modulates autophagosome-lysosome fusion [150]. Uchl1 interacts with App [199]. Its over expression decreases Aβ and NFT production [199] and lower levels of UCHL1 have been found in AD patients [200]. Regarding its autophagic role, it has been observed that UCHL1 is involved in lysosomal degradation of BACE1 [200].

Of all the described autophagic regulators potentially linked with AD, the mammalian target of rapamycin (mTOR) has been studied most investigated and is considered to play a key role in autophagy biogenesis. The mTOR protein acts as inhibitor in autophagy regulation through different pathways, including AMPK and PI3-Akt [201, 202]. In neurons and glial cells, mTOR is highly expressed an play an important role for synaptic plasticity and memory [202]. In neurons and glial cells, mTOR proteins are highly expressed, and their modulatory activities are fundamental in brain development. In the adult brain, mTOR signaling plays a crucial role in the translational initiation of protein synthesis required for synaptic plasticity and memory formation. However, uncontrolled mTOR activity leads to impairment of such processes. Numerous studies on AD brains and AD mice models revealed mTOR hyper-activation in AD brain [203]: Aβ accumulation seems to promote the activation mTOR pathway through phosphorylation of the mTOR inhibitor PRAS40 [204]. Further, hypo-energetic states may also activate mTOR [146].

Interestingly, a defective autophagy in other cells, including Astrocytes, microglia, and oligodendrocytes has also been linked to AD. In particular, disturbing basal autophagy processes in glia trigger neuroinflammation, which, as previously described, is an important pathway leading to the progression of AD [205].

2.7 Cerebrovascular abnormalities

In patients with AD, cerebrovascular abnormalities are a common comorbidity [206, 207]. These may contribute to the onset of cognitive impairment and dementia. Altered cerebral blood flow and pressure at the level of the brain are induced vascular dysfunction [208]. These events are injurious to normal brain function that would result in disturbed homeostasis, but also in blood–brain barrier (BBB) damage and micro-fractures in cerebral vases [209]. It has also been observed that the permeability of BBB to immune cells and molecules increases with aging. As said in the previous sections, the infiltration of immune cells in the brain parenchyma favors neuroinflammation [210] and ROS production [206], thus increasing the risk of AD [81].

These events are linked to the formation of Aβ plaques [211]. In particular, ROS production is related to the increase of the Advanced Glycation Endproducts (AGE) proteins and their receptors (RAGE) in the vascular system [212, 213]. A chronic hypo-perfusion state favors the formation of Aβ through the activation of the adaptive response to hypoxia and reduced clearance via perivascular draining [214, 215]. Furthermore, Aβ accumulation seems to be mainly localized in brain areas with reduced cerebral blood flow [216]. Finally, as said before, AD brains are in a pro-inflammatory state; in these conditions Notch signaling is up regulated [217]. Notch signaling has an essential role in vascular development and angiogenesis in brain through the modulation of VEGFR2 [218]. It has been observed that chronic activation of Notch1 negatively affect the brain microenvironment, in particular the delicate connection of the brain with cardiovascular system. Indeed, Notch signaling, in association with VEGF, has been demonstrated to cause impaired blood flow, further reducing the nutrients intake by neurons (worsening the already weak energetic
state). Notch also induces BBB leakages, which has severe impact on the brain and may accelerate Aβ accumulation [217]. BBB homeostasis also depends on the role of astrocytes as the act as bridge between the vascular and neuronal compartment. Several studies have observed that astrocytes go through morphological changes in proximity of vascular Aβ deposits [219]. These alterations likely occur during early stages of the disease and evidence a neurovascular uncoupling, which ultimately lead to a dysfunction of BBB barrier. It has been observed that the alteration of astrocytes induces an age-dependent accumulation of amyloid [220].

2.8 Signal transduction

2.8.1 Alteration in PKC signaling

Protein kinase C (PKC) family in mammalian is divided in three subfamily: a) calcium-dependent PKC (cPKC), necessity of DAG and Ca²⁺ presence for triggering; b) calcium-independent isoforms (nPKC), that requires DAG presence; c) an atypical isoform of PKC (aPKC) [221]. PKC isoforms are involved in several neural processes, including the ones related to cognitive function. The cPKC and nPKC isoforms could have impact on synaptic formation and plasticity, spatial memory organization or dendritic loss [221], while aPKC isoform is involved in long-term memory [222]. A deficiency in PKC isoforms signaling is thought to be involved in AD [223]. Indeed, deficiency of bPKC is correlated with Tau hyper-phosphorylation (through GSK-3β) while lack cPKC and nPKC activation down-regulates α-secretase activity [222, 224]. Furthermore, Aβ contributes to inhibit PKC isozymes [223, 224].

2.8.2 Wnt signaling pathway

The Wnt signaling pathways play a crucial role in the central nervous system during all phases of neuronal growth and development and remain significant in the adult nervous system [225]. In adults, this process is particularly important since it manages memory creation, maintenance, and behavior. Alteration of this process is strongly linked to neurodegeneration [225]. Altered function of Wnt signaling components was detected in AD brain, including down regulation of b-catenin translocation into the nucleus [226]. The reduction of b-catenin in neurons nuclei triggers the overexpression of the Wnt antagonist GSK-3b and Dkk-1 [225, 227]. GSK-3b, as discussed before, is the main enzyme in charge of tau hyper-phosphorylation. Furthermore, it participates in OS generation, which ultimately disrupts neuronal function [227].

2.8.3 Calcium role

Cellular Ca²⁺ is a key ion involved in the regulation several processes in neurons [228, 229]. Its dyshomeostasis may play a key role in the pathogenesis of AD [230] and may even precede the formation of Aβ plaques and NFTs [228].

Intracellular Ca²⁺ is usually stored in the Endoplasmatic Reticulum. Its release in the cytosol is finely controlled by multiple pathways, including RyRs and inositol 1,4,5-trisphosphate receptors (InsP3R) -related ones [231]. Even its intake from the extracellular environment is tightly regulated by multiple processes, such as the store-operated Ca²⁺ entry (SOCE) pathway and the voltage-gated Ca²⁺ channels (VGCC) [232].

As discussed before in the neurotransmission section, the physiological Ca²⁺ influx stimulates the processing of APP by α-secretase [230], thus protecting from Aβ accumulation. Imbalanced cellular Ca²⁺ contributes to pathophysiological
conditions such as accumulation of Aβ plaques and neurofibrillary tangles, protein misfolding, necrosis, apoptosis, autophagy deficits, and degeneration [230, 233].

Finally, excess cytosolic Ca\(^{2+}\) concur in mitochondria dysfunction and dysregulates KIF5-Miro-Trak-mediated mitochondrial transport to synapses [63].

High OS states and the presence of Aβ can interfere with Ca\(^{2+}\) homeostasis, releasing it from ER stores through the InsP3R and RyR [230, 234]. In addition, the increased intracellular Ca\(^{2+}\) levels in the cells interfere with the physiological function of VGCCs, thus impairing neurotransmission [230, 233].

2.9 Balance of phosphorylation: Kinases and phosphatases

Protein phosphorylation and dephosphorylation are two essential cellular mechanisms through which a wide-range of receptors and trasduction cascades are regulated. Numerous kinases and phosphatases are encoded in our genome; these two class of enzymes works balancing each other, maintaining an equilibrium phosphorylation and dephosphorylation. Impairment of such finely regulated process has been correlated with AD. As said before in this chapter, one of the trademarks of AD is the hyperphosphorylation of Tau protein, which triggers in a prion-like manner the formation of NFTs. It has been observed that Tau protein has over 85 potential phosphorylation sites [235].

There are several protein kinases that could phosphorylate Tau [236], some of them involved in the pathways discussed so far, including gsk-3β, cdk5, microtubule affinity regulated kinases (mark), tau-tubulin kinases (ttbk), Tyrosine-protein kinase Fyn (Fyn) or Tyrosine-protein kinase Ab1 (Ab1t), protein kinase A (pka), Calcium/calmodulin-dependent protein kinase (CaMKII) [236, 237]. All of these kinases have been correlated with an increased risk of AD and are capable of phosphorylate tau at multiple sites [237]. In particular, it appears that phosphorylation of Thr231 and Ser262 residues are critical for NFTs formation.

Hyperphosphorylation of Tau can also be reached and maintained through inhibition of phosphatases. Protein phosphatase 2A (PP2A) is the major enzyme that accounts for ~71% of the total tau dephosphorylation activity [238]. This enzyme co-localizes with tau and microtubules in the brain [239]. In AD, the activity of PP2A is decreased [240]. Interestingly, its down-regulation not only decrease the dephosphorylating activity but also activates CaM-KII and PKA pathways, favoring hyperphosphorylation, as it has been observed in some in vitro and in vivo studies [241, 242].

Other phosphatases have also a role in AD, including Striatal-Enriched protein tyrosine Phosphatase is an intracellular phosphatase (STEP), protein phosphatase 1 (PP1), protein phosphatase 5 (PP5), Calcineurin (PP2B), PP2C [243], through complex feedback mechanisms.

In particular, recent evidences pointed to STEP as one of the targets via which Aβ exerts its deleterious effects in AD. Elevated levels of Aβ seems to be involved in the activation of Step through the activation of α7nAChRs [244, 245] and the subsequent increase of calcium influx [245]. This triggers a cascade of molecular events (in which PP2B and PP1 are also involved) that ultimately activate STEP. STEP mediates the Aβ-induced cognitive impairment by dephosphorylation of important elements involved in synaptic plasticity and dendritic density (such as SPIN90, PSD-95 and Shank), eventually causing the collapse of synapses [246, 247].

Interestingly, the regulation of kinases and phosphatases is strictly linked to glucose metabolism, through the protein kinase AMPK (Ampk). Moreover, Aβ transiently inhibit AMPK potentially providing a link between Aβ and metabolic defects in the AD brain [248]. The activation of AMPK is correlated with glucose metabolism and is related to gluconeogenesis, IR and insulin deficiency. AMPK mediates
phosphorylation and signal transduction through GSK-3β [249], PP2A [250], beta-secretase 1 (BACE1) and sirtuin1 (SIRT1). In addition, through SIRT1, AMPK promotes autophagy. Physiologically AMPK cascade inhibits hyperphosphorylation of tau and can reduce Aβ production. Impairments of this cascade potentially lead to AD progression.

3. Conclusions

AD is one of the main causes of disability and decreased quality of life worldwide. Despite the ever-increasing number of studies, many fundamental questions remain regarding the molecular background of this disease.

The evidences derived from the recent data on AD stress its “multifactorial nature” and clearly indicate the necessity to consider wider approaches while trying to understand its biological mechanics. This chapter wanted to contribute toward and stress this new ‘pathway-like’ perspective on AD. A much deeper discussion would be needed to explore the cascades potentially linked with the disease and surely, a lot is still to be discovered. Research activity in this area is very fervid a new data is accumulating daily in the scientific community. As a final but very important note, our genes and pathways (altered or not) do respond, interacts and adapt ‘continuously’ to external stimuli. Although they were not discussed here, these environmental factors should always be considered as they can greatly influence the biological mechanisms behind multifactorial pathologies such as AD [1, 251]. Further, Epigenetic dysregulation also seems to be involved in AD as methylation mechanics [252, 253] and miRNAs signaling [254] have been found to be altered in AD brain. The key to further deepen the studies of AD would be to understand how all these processes interact and influence with each other and act in concert toward this disease progression.

Conflict of interest

The authors declare no conflict of interest.

Notes/thanks/other declarations

We want to thank all of the scientific community and people who spend their effort for the progress of our knowledge.

Nomenclature

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-HT</td>
<td>Serotonin</td>
</tr>
<tr>
<td>ABCA7</td>
<td>ATP Binding Cassette Subfamily A Member 7</td>
</tr>
<tr>
<td>ACh</td>
<td>Acetylcholine</td>
</tr>
<tr>
<td>AD</td>
<td>Alzheimer’s disease</td>
</tr>
<tr>
<td>ADAM10</td>
<td>ADAM Metalloproteinase Domain 10</td>
</tr>
<tr>
<td>AGE</td>
<td>Advanced Glycation Endproducts</td>
</tr>
<tr>
<td>AMPA</td>
<td>α-Amino-3-idrossi-5-Metil-4-isossazol-Propionic Acid</td>
</tr>
<tr>
<td>AMPK</td>
<td>5′ adenosine monophosphate-activated protein kinase</td>
</tr>
<tr>
<td>aPKC</td>
<td>atypical isoform of PKC</td>
</tr>
<tr>
<td>APOe</td>
<td>Apolipoprotein E gene</td>
</tr>
<tr>
<td>Acronym</td>
<td>Name</td>
</tr>
<tr>
<td>---------</td>
<td>------</td>
</tr>
<tr>
<td>APP</td>
<td>Amyloid precursor protein</td>
</tr>
<tr>
<td>Aβ</td>
<td>Amyloid beta</td>
</tr>
<tr>
<td>BACE1</td>
<td>Beta-Secretase 1</td>
</tr>
<tr>
<td>BBB</td>
<td>Blood Brain Barrier</td>
</tr>
<tr>
<td>BIN1</td>
<td>Bridging Integrator 1</td>
</tr>
<tr>
<td>CD2AP</td>
<td>CD2 Associated Protein</td>
</tr>
<tr>
<td>CD33</td>
<td>CD33 Molecule</td>
</tr>
<tr>
<td>CLU</td>
<td>Clusterin</td>
</tr>
<tr>
<td>CNS</td>
<td>Central Nervous System</td>
</tr>
<tr>
<td>cPKC</td>
<td>calcium-dipendent PKC</td>
</tr>
<tr>
<td>DA</td>
<td>Dopamine</td>
</tr>
<tr>
<td>DAG</td>
<td>diacylglycerol</td>
</tr>
<tr>
<td>DKK1</td>
<td>Dickkopf-1</td>
</tr>
<tr>
<td>ER</td>
<td>Endoplasmatic Reticulum</td>
</tr>
<tr>
<td>FAD</td>
<td>Familial AD</td>
</tr>
<tr>
<td>FPR2</td>
<td>formyl peptide receptor type 2</td>
</tr>
<tr>
<td>GBA</td>
<td></td>
</tr>
<tr>
<td>GSK-3b</td>
<td>glycogen synthase kinase 3 beta</td>
</tr>
<tr>
<td>iGluRs</td>
<td>Ionotrophic glutamate receptors</td>
</tr>
<tr>
<td>IL-1</td>
<td>Interleukin-1</td>
</tr>
<tr>
<td>IL-18</td>
<td>Interleukin-18</td>
</tr>
<tr>
<td>IL1β</td>
<td>interleukin 1β</td>
</tr>
<tr>
<td>IL-6</td>
<td>Interleukin-6</td>
</tr>
<tr>
<td>InsP3R</td>
<td>inositol 1,4,5-trisphosphate receptors</td>
</tr>
<tr>
<td>KIF5a</td>
<td>kinesin family member 5a</td>
</tr>
<tr>
<td>LTP</td>
<td>long-term potentiation</td>
</tr>
<tr>
<td>MAPK</td>
<td>mitogen-activated protein kinase</td>
</tr>
<tr>
<td>mGluRs</td>
<td>metabotropic glutamate receptors</td>
</tr>
<tr>
<td>Miro</td>
<td>mitochondrial Rho GTPases</td>
</tr>
<tr>
<td>mTOR</td>
<td>Mammalian target of rapamycin</td>
</tr>
<tr>
<td>NE</td>
<td>Norepinephrine</td>
</tr>
<tr>
<td>NFTs</td>
<td>neurofibrillary tangles</td>
</tr>
<tr>
<td>NF-xB</td>
<td>nuclear factor kappa light chain enhancer of activated B cells</td>
</tr>
<tr>
<td>NMDA</td>
<td>N-methyl-D-aspartate</td>
</tr>
<tr>
<td>NMDAR</td>
<td>N-methyl-D-aspartate receptor</td>
</tr>
<tr>
<td>NOX</td>
<td>NADPH oxidase</td>
</tr>
<tr>
<td>NOX2</td>
<td>NADPH oxidase-2</td>
</tr>
<tr>
<td>nPKC</td>
<td>calcium-indipendent PKC</td>
</tr>
<tr>
<td>Nrf2</td>
<td>nuclear factor erythroid 2–related factor 2</td>
</tr>
<tr>
<td>NSC</td>
<td>neural stem cells</td>
</tr>
<tr>
<td>OS</td>
<td>Oxidative Stress</td>
</tr>
<tr>
<td>PANX1</td>
<td>Pannexin 1</td>
</tr>
<tr>
<td>PI3-Akt</td>
<td>phosphoinositide-3-kinase - protein kinase B</td>
</tr>
<tr>
<td>PICALM</td>
<td>Phosphatidylinositol Binding Clathrin Assembly Protein</td>
</tr>
<tr>
<td>PINK1</td>
<td>PTEN–induced kinase 1</td>
</tr>
<tr>
<td>PKC</td>
<td>Protein kinase C</td>
</tr>
<tr>
<td>PRAS40</td>
<td>AKT1 Substrate 1</td>
</tr>
<tr>
<td>PSEN1</td>
<td>presenilin-1</td>
</tr>
<tr>
<td>PSEN2</td>
<td>presenilin-2</td>
</tr>
<tr>
<td>PTK2B</td>
<td>Protein Tyrosine Kinase 2 Beta</td>
</tr>
<tr>
<td>RAGE</td>
<td>Advanced Glycation Endproducts Receptors</td>
</tr>
<tr>
<td>RIN3</td>
<td>Ras And Rab Interactor 3</td>
</tr>
<tr>
<td>RNS</td>
<td>Radical nitrogen species</td>
</tr>
</tbody>
</table>
Perspective Chapter: Alzheimer - A Complex Genetic Background
DOI: http://dx.doi.org/10.5772/intechopen.101455

ROS  Radical oxygen species
RyR  ryanodine receptor
SAD  sporadic AD
SOCE  store-operated Ca2+ entry
SORL1  Sortilin Related Receptor 1
TGF-β  Transforming Growth Factor-β
TNF-α  Tumor necrosis factor α
Trak1  trafficking kinesin protein 1
VEGF  Vascular-Endothelial Growth Factor
VEGFR2  Vascular endothelial growth factor receptor 2
VGCC  voltage-gated Ca2+ channels
Wnt  Wingless-related integration site
α7nAChRs  α7 nicotinic acetylcholine receptor
αSyn  α-synuclein

Author details

Marco Calabrò and Concetta Crisafulli*
Department of Biomedical and Dental Sciences and Morphofunctional Imaging,
University of Messina, Italy

*Address all correspondence to: ccrisafulli@unime.it

IntechOpen

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References


Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA. 1997;278(16):1349-1356


Principles and Practice: International Journal of the Kuwait University, Health Science Centre. 2015;24(1):1-10


Biological Psychiatry. 1992;16(6):883-890


disease-like pathology. Progress in Neurobiology. 2021;206:102154


Alzheimer's Disease


[207] Sweeney MD, Sagare AP, Zlokovic BV. Cerebrospinal fluid

[208] de la Torre JC. Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovascular Psychiatry and Neurology. 2012;2012:367516


[221] Sun MK, Alkon DL. The "memory kinases": Roles of PKC isoforms in signal
processing and memory formation. Progress in Molecular Biology and
Translational Science. 2014;122:31-59


[224] de Barry J, Liegeois CM, Janoshazi A. Protein kinase C as a peripheral biomarker for Alzheimer's disease. Experimental Gerontology. 2010;45(1):64-69


[239] Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C,


mechanisms underlying enhancer modulation of neuronal identity, neuronal activity and neurodegeneration. Neurobiology of Disease. 2021;147:105155

Chapter 2

An Innovative Framework for Integrative Rehabilitation in Dementia

Valentin Bragin and Ilya Bragin

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with multiple pathophysiological mechanisms affecting every organ and system in the body. Cerebral hypoperfusion, hypoxia, mitochondrial failure, abnormal protein deposition, multiple neurotransmitters and synaptic failures, white matter lesions, and inflammation, along with sensory-motor system dysfunctions, hypodynamia, sarcopenia, muscle spasticity, muscle hypoxia, digestive problems, weight loss, and immune system alterations. Rehabilitation of AD patients is an emerging concept aimed at achieving optimum levels of physical and psychological functioning in the presence of aging, neurodegenerative processes, and progression of chronic medical illnesses. We hypothesize that the simultaneous implementation of multiple rehabilitation modalities can delay the progression of mild into moderate dementia. This chapter highlights recent research related to a novel treatment model aimed at modifying the natural course of AD and delaying cognitive decline for medically ill community-dwelling patients with dementia. For practical implementation of rehabilitation in AD, the standardized treatment protocols are warranted.

Keywords: dementia, Alzheimer’s disease, vascular dementia, cerebrovascular disease, rehabilitation, physical exercises, nutrition, cognitive training, integrative treatment, pharmacological and non-pharmacological interventions

1. Introduction

Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disorder, with multiple pathophysiological mechanisms. It currently affects more than 5 million individuals in the United States, and this number is growing daily. It is a whole-body disease, manifested by brain and body function changes during its progression. Clinically, people progressing through dementia demonstrate different manifestations of brain and body functions, including psychiatric manifestations, sensory-motor system disabilities, digestion insufficiency, and multiple bodily system involvement. A diverse combination of symptoms reflects the complexity of vascular, biochemical, physiological, and morphological changes in the brain and body during the development and progression of dementia. The amyloid cascade hypothesis has dominated the field of AD for many years. The intensive research concerning amelioration of the protein abnormalities in AD, based on the amyloid hypothesis, does not have practical value yet despite a very controversial,
accelerated FDA approval of Aducanumab, an amyloid monoclonal antibody [1]. Conventional therapies—monotherapy or combinations of multiple medications—are not able to stop the progression of the disease and have very limited modifying effects. Our present understanding of the pathogenesis of AD goes far beyond brain dysfunction and pathology. Clinical and epidemiological studies have helped to identify modifiable factors in the onset and treatment of AD. Among these, hemodynamics, muscle health, and nutritional factors have been researched in animal and clinical studies for many years. The hemodynamic factor is related to vasculature, cerebral blood flow (CBF), and structural changes in the brain. A decrease in CBF is well documented during the progression of dementia. Sensory muscle status, changes in gait, balance, and fine dexterous motor skills are all strongly connected to the initiation and progression of dementia [2].

Nutritional deficiencies begin in the early stages of AD with a loss of taste and smell, which interferes with normal digestive processes. This disruption progresses to digestive disorders, malnutrition, and weight loss in advanced stages of dementia [3].

Rehabilitation is an important part of any treatment and has gained attention from the World Health Organization (WHO). In February 2017, there was a meeting hosted by the WHO, “Rehabilitation 2030: A Call for Action.” At the event, WHO issued a call for action towards “concerted and coordinated global action to scale up rehabilitation.” Rehabilitation is very important for people living on the wide spectrum of our world’s economies and should thus be available for all medical conditions that require it, including dementia [4].

The rehabilitation of patients with dementia is an emerging concept aimed at achieving the optimum level of physical and psychological functioning in the progression of aging, neurodegenerative processes, and chronic medical illnesses. The general hypothesis for this combined therapy is based on the suggestion that every modality has a unique influence on brain functions in AD, and a combination of these modalities could have a synergistic effect, significantly slowing the rate of cognitive decline, improving quality of life, and delaying institutionalization. Nutrition and other non-pharmacological interventions, especially physical and cognitive activities, have shown promising results in delaying the onset of dementia and could potentially improve the outcome of dementia treatment. Research related to simultaneous implementation of medication and multiple non-pharmacological interventions is very limited [5, 6].

Studies relating to cognitive rehabilitation, physical exercises, and nutrition alone have shown a positive effect on cognition in animals and humans in time frames ranging from several months to several years [7–10].

Since 2000, we have developed a working rehabilitation model, utilizing all available resources, most of which are accessible to the average individual in the hopes of delaying the progression of dementia and possibly improving function in certain cognitive and physical domains. The objectives of this rehabilitation model are the activation of brain functions through the alteration of neurotransmitter activities and the increase of muscle activity, sensory input to the brain, CBF, and nutrients and oxygen supply.

To the best of our knowledge, there is no rehabilitation model related to the simultaneous implementation of multiple available modalities (medications, physical and cognitive exercises, nutrition, and sensory stimulations) for AD patients living at home. We hypothesize that the simultaneous implementation of all possible rehabilitation modalities could delay the progression of dementia significantly, when compared to the utilization of a single modality. Here, we present the key elements of this working rehabilitation model for patients living at home.
2. Pathophysiology of dementia in context of rehabilitation

2.1 Several factors in the pathogenesis of dementia

Our understanding of pathophysiology in dementia has shifted in focus from amyloid accumulation to hemodynamic and energetic metabolism changes in the brain. It is a chronic, progressive disorder that affects the entire body [11]. Amyloid accumulation in the brain is a dynamic process in response to different etiological factors: stress, hypoxia, loss of subcortical nuclei (the nucleus basalis of Meynert, the locus coeruleus, and the raphe nucleus) [12–14].

The hemodynamic factor is related to the development of hypoxia- and hypoxia-related metabolic and structural changes in the brain. Hypoperfusion affects white matter, subcortical nuclei, and the cortex of the brain in people with dementia. Chronic hypoxia decreases energy production in the brain, affecting protein synthesis pathways, which cause the development of reversible and irreversible morphological changes in the brain structure. During dementia progression, there are cerebral cortex and cortical corpus callosum atrophy, white matter damage, and dysfunction of subcortical nuclei. Alzheimer’s dementia often begins as a disease of small blood vessels that are damaged by oxidation-induced inflammation and dysregulated amyloid metabolism, which may be seen as implications for early detection and therapy [15]. Today, there is an overlap between Alzheimer’s disease and cerebral vascular dementia. Vast evidence from epidemiological, neural, physiological, clinical, and pharmacological studies suggests common pathogenic pathways between these two types of dementia and highlights the vital roles of vascular pathways in dementia development and pathology. The deficiency of cerebral blood flow could be a reason for neuronal dysfunction, white matter damage, and death of brain cells in both types of dementia.

The course of dementia is associated with progressive changes in cardiovascular pathology in the brain, increased numbers of micro and lacunar infarcts, cerebral atrophy, white matter changes, and signs of demyelination [16, 17]. CBF changes have been well documented in normal aging, MCI, and dementia by using different imaging techniques, such as single-photon emission computed tomography (SPECT), functional magnetic resonance imaging (fMRI), positron emission tomography (PET), among others. On an rCBF—SPECT test, people with mild AD showed a significant reduction in rCBF in the left parietal cortex during an episodic memory task [18]. The conversion from MCI to AD, as well as the progression of AD, is associated with CBF changes. The lower the patient’s CBF, the faster and more drastic is their decline of Mini-Mental Status Exam (MMSE) scores [19].

The first notable changes in CBF start in the entorhinal and hippocampal areas of the brain, eventually expanding into the temporal and parietal lobes until finally reaching the frontal lobes [20]. In some places of the brain such as the sensory-motor strip areas and the cerebellum, CBF is relatively well-preserved in dementia [21]. This fact helps our understanding and explanation of the preservation of procedural memory in dementia, which is initiated in sensory-motor areas of the brain [22].

Moreover, judging from the same studies, it is quite possible to suggest that regulation of CBF is preserved as well, at least in the sensory-motor strip and cerebellum in moderate stages of the disease. Another example of preserved CBF in dementia is the report concerning increased CBF in frontal-occipital cortex in mild–moderate AD patients (7 affected people), compared to the control group (8 healthy individuals) during a visual face-matching task [23].

Energetic crises include mitochondrial failure and a decrease in the flow of substrate in brain neurons. A decrease in energy production in the central nervous
system is one of the key factors in pathogenesis of dementia, which profoundly changes neuron function. On the peripheral level, there are well-documented changes in sensory-motor system; decrease in feelings of taste, smell, and number of proprioceptive receptors; changes in mobility of joints and spine; increase in muscle spasticity; and decrease in muscles blood flow. Chronic muscles hypoxia is associated with muscle atrophy and sarcopenia. The decreased number of receptors and their functions result in diminished sensory input to the brain, and compromised CBF and neurotransmitters activities.

2.2 The 3M’s dementia assessment model™ for dementia

Dementia has a progressive course of cognitive decline and physical disability, negatively affecting the quality of life, the capacity to socialize, and the ability to perform everyday activities. From a practical point of view, we developed the 3M’s dementia assessment model™ for dementia evaluation, which includes assessing memory, mood, and movements. It is displayed in Figure 1.

Dementia can start from any of them, alone or in combination with each other. All factors could be affected at different speeds, and all of them have to be taken into consideration during dementia evaluation [24, 25]. Movements, general slowness, and fine motor skills could start before the development of the cognitive problems in dementia [26].

3. Modifiable factors in context of rehabilitation

Each of these modifiable factors could affect disease progression and treatment.

3.1 Stress

Acute and chronic stresses can affect brain and bodily functions by mobilization of sympathetic nervous system and activation of hypothalamic–pituitary–adrenal (HPA) axis on different stages of stress. Since Hans Selye’s discovery of the general
adaptation syndrome, countless publications demonstrate relationships between stressors, stress response, and diseases in animal and clinical studies [27]. Stress affects physiological and biochemical processes in every organ in the body during dementia initiation and progression [28]. Sensitivity to stress events increases with aging and may accelerate cognitive and physical decline in dementia [29]. Acute stress affects attention and memory [30]. Chronic stress could play a role in development and progression of dementia by persistent activation of fundamental surviving pathophysiological, mechanisms [31, 32]. There are links between chronic stress and level of memory loss in MCI and dementia [33]. Stress-related hormones mobilization is manifested in failures of homeostasis, thus leading to various diseases, including dementia [34]. Stress affects physiological and biochemical processes in every organ and system in the body during dementia initiation and progression [28].

They may be bidirectional relationships between stress and dementia. Stress is associated with CBF redistribution, mitochondrial and multiple neural pathways changes, and decreased attention and memory [35]. However, during dementia progression, loss of memory, behavior, and social communications could be stressors and evoke stress response by themselves.

There is related data utilization of different interventions aimed at modulation of stress response; the practical recommendations are in the early stages of research [36]. Effective stress management activities could be helpful for patients with dementia and their caregivers and need to be included in dementia treatment strategy [36, 37].

3.2 Depression and other emotional problems

Depression like dementia is a whole-body disease, affecting brain metabolism, sensory systems, muscle health, and nutrition. Depression could share common pathophysiological mechanisms with dementia, such as hypoperfusion, hypoxia, oxidative stress, and energetic and neurotransmitters failure and stress. Depression is one of the risk factors for developing dementia [24].

Depression could precede dementia and accompany dementia progression. The “vascular depression” hypothesis has been proposed, based on clinical, physiological, and morphological changes in seniors, suffering from persistent depression [38]. Clinical and radiology data and epidemiological studies demonstrate the changes in brain structure in dementia in old-old patients [39]. Treatment of late-life depression with vascular pathology is a challenging task for clinicians.

Apathy and anxiety may be seen in depression and dementia affecting the course of these diseases and associated with detrimental effects on activities of daily living [40–43].

3.3 CBF and vascular pathology

The fact that cardiovascular pathology occurs in multiple neurodegenerative processes in dementia is well documented. However, it remains necessary to investigate the interconnections and order of occurrence of these two factors [44, 45]. The course of dementia is associated with progressive changes in cardiovascular pathology, increased numbers of microbleeds and lacunar infarcts, cerebral atrophy, white matter changes, and signs of demyelination [17].

Vascular pathology and decrease of CBF contribute to progression of clinical manifestations, improving cognitive and physical functions, and developing morphological changes in dementia. Changes in CBF, cerebral ischemia, and hypoxia negatively affect substrate delivery, necessary for energy production and protein synthesis and essential neuronal activities [46].
### 3.4 Digestive system

In epidemiological studies, nutrition has been under investigation for many years as an important factor contributing to healthy aging and prevention of dementia and multiple chronic diseases. For the purposes of this discussion, the nutritional aspect in the treatment of dementia can be separated into four components.

The first component is related to the diet. There is currently no consensus regarding a diet geared towards at least partially normalizing brain metabolism in dementia. Along with the well-known Mediterranean diet, calorie-restrictive diets, as well as ketogenic diets, may have a beneficial neuroprotective effect in aging and multiple neurodegenerative diseases [47]. The diet close to that used for cardiovascular pathology and diabetes with some modification geared towards very low carbohydrate products is probably the most suitable diet to be offered for dementia patients.

The second component is a number of vitamins and nutriceuticals, which have been known to affect critical biochemical pathways involved in the pathophysiology of dementia. Among them are vitamins and nutrients that are a part of the normal metabolic processes and become deficient during stress, lack of exercises, hypoxia, and many other clinical conditions. In a controlled study on institutionalized, moderate-to-severe dementia patients taking a vitamin/nutriceutical combination for 9 months demonstrated a significant delay in decline on the Dementia Rating Scale and clock-drawing test, compared to those receiving placebo. The vitamin-nutriceutical combination in this study was designed to support antioxidant activities, energy production, and protein synthesis. This small study supports the notion that even in severe dementia, there is still room for stabilization of disease progression [48]. The specific research data related to different nutritional substances and vitamins is out of scope of this chapter.

General recommendations include products that are rich in antioxidants and include dietary precursors for mitochondria function, protein metabolism, and membrane phosphatide synthesis [6, 49].

The third component is associated with changes in gastrointestinal functions in every part of the GI system. These begin in the early stages of dementia and worsen with disease progression, frequently manifested as nutritional disorders such as anorexia, poor digestion, malnutrition, and weight loss. The loss of taste and smell develops in the early stages of dementia, results in the loss of appetite, and negatively impacts all stages of digestion. Even in the early stages of AD, community-dwelling patients display poor nutritional consumption [50]. Patients with dementia often forget to eat or drink on time. In the advanced stages of dementia, progressive GI malfunctions occur simultaneously with chewing and swallowing problems, dysphagia, and a decreased feeling of thirst, all of which are connected to poor food digestion and absorption, vitamin deficiencies, decreased immunity, loss of muscle mass, increased frequency of infection, poor balance, and falls [3]. Weight loss is associated with severity and mortality in AD and is an indicator of protein, energy, vitamin, and nutrient deficiency [51]. According to these authors, in the middle stage of AD (MMSE—16.6 ± 4.9), significant weight loss is observed in more than 40% of patients living at home.

The presence of malnutrition in dementia could be a result of GI system dysregulation: changes in appetite, weight, and GI motility, and the probable development of exocrine pancreatic insufficiency.

An indicator of pancreatic exocrine insufficiency is the level of fecal elastase-1 in stool, the concentration of which decreases progressively with age. Pancreatic exocrine insufficiency was seen in 21.7% of people over 65 years without
gastrointestinal disorders, surgery, or diabetes [52]. Pancreatic exocrine insufficiency is more prominent in patients with insulin-dependent diabetes [53].

The existence of pancreatic insufficiency during the aging process and in diabetes, as well as changes in glucose metabolism in dementia, makes it quite possible that exocrine pancreatic insufficiency plays an important role in the digestive malfunctions in dementia.

The fourth component is the microbiome. Imbalance in gut flora can negatively affect general health. The first connection between intestinal microbiome and longevity was described over a century ago by Elie Metchnikoff [54]. Research about the gut-brain axis demonstrates the strong bidirectional connections between gut–body health. Gut flora participates in production of serotonin, dopamine, and GABA—neurotransmitters, actively affected in many neurodegenerative illnesses and medical diseases as well. Stress, depression, and dementia negatively influence the health of the gut. A practical recommendation about using probiotics, prebiotics, and postbiotics for depression and dementia is on the horizon [55–57].

3.5 Medical illnesses

Medical illnesses (cardiac problems, diabetes, etc.) are risk factors for dementia development and progression. In recent years, accumulating evidence of research has suggested that cardiovascular pathology, especially irregular pulse, could be associated with dementia progression. In diabetes mellitus (type 2), there are metabolic changes, which affect vasculature and cell functions in every organ in the body. The cognitive and physical decline in dementia became worse with progression of diabetes.

The treatment and stabilization of these medical illnesses and disorders have a positive effect on people with dementia. The same approach could be applied to diseases related to the transport of oxygen to the organs (anemia, pulmonary pathology, and renal problems).

3.6 Cognitive activities

Mental activities have a positive effect on CBF in healthy individuals and have been shown to delay the onset of dementia [58]. Research related to improving CBF in AD patients through the use of cognitive activities is slowly growing. Recently a program of mental exercises for nursing home residents with mild AD showed an improvement in cognitive function after being implemented for 6 months. This program was based on extensive previous research done by the same research team relating to increased CBF during various mental tasks [59].

3.7 Physical activities

The connections between physical activities and rCBF are well established and done on healthy seniors, patients with MCI, and animal dementia models [60]. Physical exercise is considered a preventative or disease-modifying intervention, as it has shown a neuroprotective effect in brain aging [61]. Physical activities increase level of BDNF, which is responsible for brain health [62].

The effects of resistance training and aerobic exercises are connected to increased activity of the entire cardiovascular system and CBF simultaneously. These physical activities increase level of BDNF, which actively participate in learning, memory, and mood [63].

Hand exercises are more suitable and safer for fragile medically ill patients with all stages of AD because they can be done in a seated or laying position and appear to be a practical model for a home-based exercise regimen [11].
Simple hand movements have been shown to increase CBF in contralateral hemisphere of healthy subjects [64]. An increase in CBF during meditation, with simultaneous chanting and finger movements (dual tasks), has been observed by SPECT in healthy volunteers [65].

Physical activities have positive effect on neuropsychiatric symptoms in dementia [37].

Physical and mental exercises alone, as well as a combination of the both, could modify CBF and improve cerebral metabolism, decrease hypoxia, increase availability of oxygen and nutrients to brain cells and structures, increase brain vitality and prolong an active life for patients with dementia.

4. Rehabilitation model for dementia

Rehabilitation of AD patients is an emerging concept aimed at achieving optimum levels of physical cognitive and psychological functioning in the presence of neurodegenerative processes, aging, and progression of chronic medical illnesses.

Given the complexity regarding the pathogenesis of AD, we hypothesize that the simultaneous implementation of multiple rehabilitation modalities could delay the progression of dementia. To the best of our knowledge, there is no rehabilitation model designed for the treatment at home for many years. This program starts in the doctor’s office and continues in the home indefinitely.

4.1 4M’s dementia rehabilitation model™ for dementia

From a practical point of view, we approach dementia rehabilitation with the 4M’s dementia rehabilitation model™, which includes treating memory, mood, movements, and mitochondria to increase the vitality of neurons and their connections by increasing CBF, as shown in Figure 2.
4.2 Office and home parts of the program

The in-office part of the model includes (a) an assessment of cognitive functions and movements, with special attention paid to preserved areas in cognition and motor system; (b) education about AD, modifiable factors, which needs to be used; (c) teaching patients and caregivers stress reduction techniques, as well as appropriate physical and cognitive exercises, based on patient’s level of dementia; (d) physical and cognitive training during office visits; and (e) monitoring of treatment progress during subsequent office visits.

The home part of the model includes (a) physical exercises, cognitive training, and stress management techniques practiced as per the workbook and videos (which are given to each patient); (b) sensory activation (light, sound, relaxation videos with tranquil nature scenery; and (c) nutrition.

The physical and cognitive aspects of the rehabilitation program have been developed based on the physiological, real-life interplay between physical activity, attention, and procedural memory. Physical activities require attention and help with procedural memory. All of them have a direct effect on CBF [64–66]. During the progression of AD, all three components deteriorate at different rates over time. However, they are relatively preserved, compared to other cognitive functions until the late stages of AD.

Over the years, preservation of cognitive function has been demonstrated up to 72 months of treatment. Remaining at the same level of cognitive function at the initial visit is a significant treatment achievement [67, 68].

Even though the progression of dementia is going along with development of chronic hypoxia, there is still room for developing neuroplastic changes in response to sensory-motor stimulation [69]. In recent review, ischemic damages evoke an initiation of network reorganization in spared areas of the brain [70].

4.3 Rehabilitation in chronic versus acute brain diseases

There are different goals for rehabilitation for chronic and acute brain diseases; even all available rehabilitation modalities are implemented simultaneously in both types of rehabilitation. The goal of rehabilitation in dementia is to prevent cognitive and physical decline and to preserve the level of functioning and the quality of life for as long as possible. Rehabilitation activities for people living at home have to continue without time limits, for many years. Home program refers to activities designed for joint patient and caregivers, which increase patient–caregiver connections. The office staff get training, related to interaction with patients and their caregivers. Much attention is placed on education and support of caregivers as well. Elements of physical, occupational, and speech therapy in outpatient clinics could be provided by office staff in the office and by caregivers at home. Cognitive and physical stabilization is expected, as demonstrated in Figure 3.

In stroke and head trauma (acute brain catastrophes), the goal of rehabilitation is to return to the premorbid level as close as possible. Rehabilitation in this case is
Alzheimer’s Disease

a time-limited process, lasting from several months to several years. Cognitive and physical improvement is expected, as shown in Figure 4.

4.4 Six pillars of rehabilitation

The six pillars of the program consist of pharmacological interventions, mild physical exercises, multisensory stimulation, cognitive training, nutrition, and emotional support. Each pillar has direct and indirect effects on the elements of the 4M’s Dementia Rehabilitation Model™.

Medications and supplements comprise the first pillar in this model. Cholinesterase inhibitors, NMDA receptor antagonists, antidepressants, neuroleptics, and mood stabilizers, along with medication for sleep and pain, are used when clinically appropriate. Supplements include vitamin D3, B-complex, fish oil, folic acid, alpha-lipolic acid, acetyl-l-carnitine, inositol, Ribose, and other vitamins.

Mild physical exercises are the second pillar in this rehabilitation. Muscle activities couple with increasing brain blood flow and simultaneously attention and procedural memory training. Exercises are designed for people with extremely limited physical capacities and problems with gait and ambulation. The physical exercises are safe and done in sitting positions and can be performed in the doctor’s office or at home.

Physical exercises mainly consist of simple, coordinated hand and leg exercises performed both with and without the use of simple objects, such as a tennis ball. Dual-task exercises consist of hand movements, coupled with counting and breathing. Special exercises have been developed for balance training and include eye movements for decreasing visual fields and working with neck movements.

Multisensory stimulations include pleasurable activities related to auditory, visual, and tactile and other sensory channels. For example, patients work on pegboards to increase finger mobility and right–left coordination, or patients read tongue twisters loudly, sing songs, or watch comedians.

Attention and memory training consist of computerized attention (“go, no-go”) and working memory exercises (“N-back” paradigm), tasks that are performed in the doctor’s office with different objects (words, numbers, shapes, pictures, textures) plus pen and paper cognitive exercises, performed at home.

Nutrition includes diet and digestive support for microbiome and pancreatic enzymes, if clinically indicated (loss of weight).

Emotional support consists of implementation of stress management tools, brief educational sessions, related to family relationships, psychotherapy for patient’s emotional reactions in response to decline of cognitive and physical functions.

For caregivers, there are psychotherapy sessions for developing coping strategies to manage behavior problems in dementia and to recognize symptoms of burnout syndrome. The family understanding and support help dementia victims stay at home for a long period of time.
5. Clinical cases

Here, we present two cases with mild dementia stabilized over years with an integrative treatment approach.

5.1 Case 1

Patient was an 87-year-old, retired engineer, who first came to our office at age 68. Her diagnosis was mild dementia with episodes of depression, anxiety, insomnia, HTN, diabetes, neuropathy, arthritis, dizziness, and gait problems. Her current psychiatric medications are memantine, gabapentin, clonazepam, zolpidem, bupropion SR, donepezil, vitamin D, lovaza, magnesium oxide, B-complex, and folic acid.

This patient has been treated for 19 years (2001–2020). Cognitive assessments include the MMSE, clock-drawing task, verbal fluency animals, and verbal fluency letters tests. She was doing full rehabilitation protocol with any new modifications, which had been developed during this time interval in our office.

As you can see in Figures 5–8, this patient has been stable for the whole period of treatment based on the results of these 4 tests.
5.2 Case 2

This patient was a 92-year-old female, retired clerk, who came for treatment at age 74. Her diagnosis was mild dementia with episodes of depression, anxiety, insomnia, HTN, CAD, diabetes, arthritis, dizziness, and gait problems. She had a mini-stroke in 2015. Current medications are Namenda, Trintellix, B-complex, folic acid, and magnesium oxide.
An Innovative Framework for Integrative Rehabilitation in Dementia
DOI: http://dx.doi.org/10.5772/intechopen.101863

This patient has been treated for 16 years (2002–2020). Cognitive assessments include Mini-Mental Status Examination (MMSE), clock-drawing task, verbal fluency animals, and verbal fluency letters tests. She was doing full rehabilitation protocol with any new modifications as in the previous case 1.

After mini-stroke (2014–2015), her MMSE dropped to 22 and then returned to 25.

As you see in Figures 9–12, this patient has been stable for the whole period of treatment.

6. Discussion

The theoretical basis of this rehabilitation model is rooted in emerging research related to neuroplasticity data. Other well-known facts regarding AD pathogenesis—including chronic hypoperfusion and hypoxia, oxidative stress, and mitochondrial and bioenergetics failure—also provide a solid theoretical foundation upon which to effectively design and test different treatment modalities available for rehabilitation in AD [69–71]. Additionally, modifiable risk factors for AD development and progression continue to be identified [72].

In a broader sense, rehabilitation in AD could include medications that are available today (and those that will become available in the future), in addition to all possible non-pharmacological modalities that are aimed at stabilizing brain and body functions, with special attention to physical and cognitive exercises, sensory stimulations, and dietary modifications.

The rehabilitation of AD has to be seen as an ongoing treatment approach not limited by time constraints. It can be adapted to the different stages of this illness, including even the preclinical stage.

Not all motor and cognitive functions are equally affected in AD. At various levels of dementia and in each cognitive domain, there is a time-related evolution of brain disability. Meanwhile, there is a growing body of data related to the preservation of some of the brain functions in AD, including certain learning and procedural memory capacities, emotional and movement controls, and the ability to use external memory aids [72–76].

The multifaceted rehabilitation model for home usage presented here demonstrates strategies that go beyond the prescribing of medications to alleviate AD progression alone. It is a dynamic framework that is open to the addition of any newfound medications or innovations in nonpharmacological interventions. This model is based on a proactive, 24/7 approach to battling AD—starting with doctor’s office visits and continuing into the patient’s home for an indefinite period of time.

These rehabilitation strategies become meaningful only with ongoing support from caregivers who help the patients at home with nutrition and everyday physical and cognitive activities. This model is flexible, and the key to it is to use all the five
elements of the program simultaneously. This kind of simultaneous approach is already commonly used in the treatment of many other progressive chronic ailments, such as cardiac problems, dyslipidemia, hypertension, and diabetes.

The cost for implementation of this home-based rehabilitation model is minimal (workbook, videos, and tennis ball). In addition, this model may ease the financial burden of this deadly disease on the health care system as a whole by reducing secondary medical problems from progressive dementia and delaying nursing home placement.

7. Conclusion

A multifaceted rehabilitation model for dementia at home offers a promising strategy for postponing cognitive and physical decline in dementia. Modifiable factors in dementia could be implemented at low cost.

The development of comprehensive therapy models for rehabilitation in dementia is a matter of time. There is an urgent need for the designing of long-term studies, in which all available modalities will be simultaneously implemented and for as long as possible. Further research is needed to assess the efficacy and economic impact of this multifaceted rehabilitation model.

8. Summary points

• Epidemiological studies have identified a number of modifiable factors in the onset and progression of dementia.

• A new understanding of the pathogenesis of dementia has revealed that protein changes in the brain develop simultaneously with cerebrovascular pathology.

• Progression of clinical dementia depends on the stress, emotional reactions, CBF, digestive system, medical illnesses profile, cognitive activities, and muscle health.

• Physical and mental activities may contribute to the delay of the onset of dementia and slow down the disease progression.

• A novel treatment model for dementia patients is the simultaneous use of nonpharmacological modifiable factors and pharmacological interventions for many years.

Acknowledgements

Thank you to Vian Shekhtman and Nora Zagranichny for their assistance in preparation of this chapter.

Conflict of interest

The authors declare that they have no competing interests. The authors have no financial interests in this project.
Disclaimer

No grant support was received for this project.

Notes/thanks

I want to thank the patients that have been treated in our center. Their participation and feedbacks were very valuable, and we are grateful for it.

Author details

Valentin Bragin1* and Ilya Bragin1,2,3

1 Stress Relief and Memory Training Center, New York, United States of America

2 St. Lukes University Health Network, Pennsylvania, United States of America

3 Lewis Katz School of Medicine at Temple University, Pennsylvania, United States of America

*Address all correspondence to: val11235@gmail.com

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References


[16] Herholz K, Carter SF, Jones M. Positron emission tomography imaging


[44] Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta
Neuropathologica. 2010;120(3):287-296. DOI: 10.1007/s00401-010-0718-6


[63] Sama FS et al. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate. eLife. 2016;5:e15092. DOI: 10.7554/eLife.15092


Chapter 3

Alzheimer’s Disease: An Insightful Review on the Future Trends of the Effective Therapeutics

Afreen Hashmi, Vivek Srivastava, Syed Abul Kalam and Devesh Kumar Mishra

Abstract

Alzheimer’s disease (AD) is a disorder of brain which progressively weakens the cognitive function. It is occur due to formation of β-amyloid plaques, neurofibrillary tangles, and degeneration of cholinergic neurotransmitter. There is no effective treatment capable of slowing down disease progression, current pharmacotherapy for AD only provides symptomatic relief and limited improvement in cognitive functions. Many molecules have been explored that show promising outcomes in AD therapy and can regulate cellular survival through different pathways. Present study involves current directions in the search for novel, potentially effective agents for the treatment of AD, as well as selected promising treatment strategies. These include agents acting upon the β-amyloid, such as vaccines, antibodies and inhibitors or modulators of γ- and β-secretase; agents directed against the tau protein. Current clinical trials with Aβ antibodies (solanezumab, bapineuzumab, and crenezumab) seem to be promising, while vaccines against the tau protein (AADvac1) are now in primary-stage trials. Most phase II clinical trials ending with a positive result do not succeed in phase III, often due to serious side effects or lack of therapeutic efficacy but Abucanumab (marketed as Aduhelm) now approved by USFDA in 2021 for the treatment of AD.

Keywords: neurodegeneration, novel strategies, clinical trials, medicinal plants

1. Introduction

Alzheimer’s disease (AD) is a brain disorder described in 1906 by Aloes Alzheimer, a German physician [1]. It is a progressive and neurodegenerative disorder which mainly occur in old aged people of over 65 years of age [1–3]. For progression and development of disease various pathways are involved such as formation of plaque, inflammatory cascade, cholinergic deficit, oxidative stress, and many more. Senile plaques formation and neurofibrillary tangles persist significant neuro-pathological symbols of this disease. Senile plaques are the main component of amyloid beta (Aβ) peptide that are covered by dystrophic neurites and activated microglia. Accumulation of Aβ results changed process of proteolytic amyloid precursor protein (APP) through beta and gamma secretase. The β-amyloid peptide, with 39–42 amino acid residues (BAP), perform vital role in development of AD.
There are mainly two types of AD, familial AD which affects the people who have age less than 65. The other type of AD is sporadic AD which affect the people older than 65. At present there is no cure for Alzheimer’s disease but it could me managed to some level by using available medications (Table 1) [6, 7].

1.1 Epidemiology

In 2020 approx. 50 million individual dealing with dementia worldwide. In India more than four million of people suffering from AD and dementia while in USA approx. 5.8 million living with dementia and AD. It is estimated that it is the fifth main source of death in USA and the number of death increased 146% between 2000 and 2018. It is predicted the causality will increase to 13.8 million which number of patient increases to 13.5 million by 2050. Elderly persons are more prone to younger one [8].

1.2 Etiology

In maximum case genetic lifestyle choices aging stress and environmental factors induces AD [9].

1.2.1 Age

Researchers have claimed that older adults have more risk of having AD. Scientists are still learning, how age-related changes in the brain may harm neurons and contribute to Alzheimer’s [10].

1.2.2 Genetic factors

1.2.2.1 Early onset

It occur due to mutation in chromosome 1, 14, and 21. The changes on chromosome 1 produces PRESENILIN-2 (PSEN2) named protein while chromosome 14 produces PRESENILIN-1 (PSEN1). These PSEN 1 and PSEN 2 directly and indirectly both trigger/encode for membrane protein convoluted for amyloid precursor protein. These mutations reduce the effectiveness of \( \gamma \)-secretase, an enzyme which is responsible for formation of beta amyloid peptide (\( \beta \)AP) [11]. Amyloid precursor protein is

<table>
<thead>
<tr>
<th>Factors</th>
<th>Dementia</th>
<th>Alzheimer’s disease</th>
<th>Normal aging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>CNS disorder due to disease or any other pathological condition.</td>
<td>Common form of dementia.</td>
<td>Condition occur due to programmed cell death with time (gene therapy) and causes various disability.</td>
</tr>
<tr>
<td>Cause</td>
<td>AD, stroke, thyroid issues, vitamin deficiency, etc.</td>
<td>Deposition of beta amyloid protein in brain.</td>
<td>May cause biological systems to fail (DNA oxidation, DNA methylation, and apoptosis).</td>
</tr>
<tr>
<td>Duration and age</td>
<td>Permanent damage and 65 years and older.</td>
<td>Average 8–20 years and 65 year but can occur as early as 30s.</td>
<td>Gradual and progressive condition until death.</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Issues with memory, poor judgment, less focus and attention.</td>
<td>Difficulty to remembering newly learned information.</td>
<td>Bone break more easily, decrease overall energy, greater risk of heart stroke or hypothermia.</td>
</tr>
</tbody>
</table>

Table 1. Alzheimer’s disease versus dementia and normal aging [4, 5].
coded on chromosome 21 and this mutation results in overproduction of beta amyloid peptide. Mutation on chromosome 1, 14, and 21 results in early onset AD [12].

1.2.2.2 Late onset

Apo-lipoprotein E (APOE) gene is responsible for late onset AD. APOE gene is lipid metabolism regulator which has an affinity for beta amyloid protein and increases the risk of AD. Chromosome 19 produces APOE gene. The inheritance of APOEe4 allele own genetic risk in sporadic AD. APOEe4 allele, age elevate the risk for development of late AD by two to three folds and two copies of five folds [13].

Variations in gene for receptor sortilin, SORT1, that is important for transferring APP from surface of cell to Golgi-endoplasmic reticulum complex, have been found in familial and sporadic types of AD [14].

1.2.2.3 Environmental factors

Conditions such as heart disease, stroke, high blood pressure, diabetes, and obesity are also linked as risk factors for AD [15].

2. Pathogenesis and clinical findings

The real origin of this disease is not well known but problems are linked with brain protein that work abnormally and cause malfunction. As a result neurons were damaged then fail to connect other neuron as a result they die. Initially the degradation starts within the region of brain which control memory ultimately dementia occur (Figure 1) [17].

Figure 1.
Clinical findings in Alzheimer’s disease [16].
2.1 Beta-amyloid protein aggregation and deposition

In the initial stage of AD amyloid proteins work abnormally and cause overproduction of beta amyloid secretase named enzyme split amyloid processor protein and due to deviation from this process, especially sudden change in gamma and beta secretases leads to unnatural production of amyloid beta [18].

2.2 Neurofibrillary hypothesis

Tau protein is known for its stabilizing property. It is useful in the transportation of nutrients and others essential matter within the neurons while in AD. Tau protein cause mutation and changes its structure which is known as neurofibrillary tangles [18, 19].

2.3 Cholinergic hypothesis

It is observed in the patient of AD there is deficiency of ACh due to abnormal functioning of choline acetyl transferase. This will treat as a clinical hallmark to support cholinergic hypothesis there is also a possible treatment of AD by increasing the level of ACh by reducing the activity of AChE cholinergic depletion observed after neurodegenerative cascade various cholinesterase inhibitors currently used in the treatment of AD [20].

2.4 Excitotoxicity

It is defined as the excess interaction of neurotransmitter glutamate and other excitatory neurotransmitter which may act as a potent neurotoxins for Alzheimer [21].

2.5 Vascular diseases and high cholesterol

Apo-lipoprotein E play important role in the cholesterol transportation and catabolism of triglyceride lipoprotein. Cholesterol also alter the clearance of amyloid beta and generation of NFT in neuronal membrane APOE4 also enhance the deposition of beta amyloid protein. High level of cholesterol in brain there by alter the member functioning this leads to plaque formation resulting AD [22].

2.6 Oxidative stress

Oxidative stress is generated due to imbalance of ROS generation and its quenching. Brain is more prone for oxidative stress due to high consumption of O$_2$. High level of polyunsaturated fatty acid. Low level of antioxidants and high level of redox transition metal ions. These all factors facilitate the production of reactive oxygen species like superoxide, hydrogen peroxide, etc. These ROS interact with surroundings proteins nucleic acids, etc. and cause cellular dysfunction [23]. There is also a close relationship between amyloid beta and oxidative stress because amyloid beta elevate the formation of ROS and initiate mitochondrial damage. This will also cause oxidative damage. These effects can also be observed in brain of triple transgenic mouse model of AD where tocopherol and GSH level decrease while lipid peroxidation is increased [24]. However this was observed before any plaque formation. While in another model dual mutant APP was expressed, oxidative stress and inflammation was induced by thiamine deficiency provoke plaque formation and enhance the level of amyloid [25].
2.7 Mitochondrial dysfunction

It is observed in the morphometric analysis of AD patients' brain showed significant deficiency of mitochondria, while its DNA and protein concentration elevate in cytoplasm and in the vacuoles associated with lipofuscin [26]. These mitochondria may be damaged due to autophagy and oxidative stress. Mitochondrial cytochrome oxidase activity also reduced in cortical region of AD brain. Due to this deficiency mitochondrial dysfunction occur and ROS generated and energy stores were decreased and ultimately neurodegeneration occur [27].

2.8 Inflammatory mediators

Amyloid deposition in brain also associated with local inflammation and immunologic alleviations [28]. This association induces the release of NO3, cytokines which cause neural damage and cause inflammation [29, 30].

3. Role of sex hormone in Alzheimer's

Evidence from animal and human studies support functional roles of sex hormones like estrogens, progesterone, and androgens in behavior and cognition. With several neuroprotective activity involved, age reduces level of sex hormones were connected with greater possibilities of cognitive degeneration and AD. For example, in females development of AD is associated with decreased exposure to estrogens across the lifetime, while in males age related degeneration in both levels of peripheral and brain testosterone is linked with greater susceptibilities of AD development. Also, alterations in receptors of sex hormone and downstream signaling pathways during aging have been stated. For example, the nonfunctional splicing estrogen variants receptor alpha in the hippocampus was enhanced throughout aging and AD, with advanced levels in female old age subjects in comparison to males. Moreover, studies recognized polymorphisms of estrogen receptors related with intellectual decay and AD development in females, especially in APOE ε4 (APOE4) transporters. These information recommended diminished responsiveness of brain to sex hormones during aging and disease development. However, clinical trial outcomes of sex hormone therapy in AD are rather contentious. Despite prior studies associating protective activity of estrogen replacement against AD in females, huge clinical studies failed to exhibit any useful possessions. It was suggested that replacement of hormone initiation in the serious window of perimenopause may diminish the risks of dementia, while it might raise the risks if started a very long time after menopause. Moreover treatment timing, reduced responsiveness at receptors of brain and downstream signaling pathways might add to the uselessness of hormonal therapy. Together, these investigations recommend the complication of sex hormones association in AD [31].


4.1 Conventional approaches

Currently there is no cure for this disease, the objective of several medicine is used to reduce symptoms linked with disease and to reduce disease progression (Table 2) [32–36].
Alzheimer’s Disease

4.2 Current scenario

4.2.1 Antiamyloidogenic pathway and amyloidogenic route as approaches for development of therapeutic treatments adjusting the course of Alzheimer’s disease

From the previous eras, the pharmaceutical industry has decided to chiefly focused on the amyloidocentric method, dedicating significant possessions to form useful AD drugs. Nevertheless, numerous failures of drug candidates in clinical trials have led investigators to question the viability of this approach [10–12]. Possible cause for failure is a absence of biomarkers that could consistently recognize AD in comparatively initial phases. It is totally promising that the patients presently enrolled for phase III trials are in such advanced phases of AD that any attempted interference is possibly inadequate. In the meantime, there is still a number of new management under development, that focused the amyloidogenic route. In order to decrease generation of Aβ from the APP, inhibition of γ- and β-secretase and the potentiation of activity of α-secretase have been deliberated.
Inhibitors and modulators of β-secretase

β-secretase enzyme complex contributes in the primary phases of the amyloidogenic APP-processing pathway. The inhibitors of β-secretase development is a task because, besides the APP, this complex has several substrates. To give just one example, neuregulin-1, that included in the CNS axons myelination and synaptic elasticity, is a target β-secretase. Substrates wide range results to substantial adverse effects, even if the precise enzyme inhibition is reached. But, E2609 (clinical trial ID# NCT01600859), MK-8931 (NCT01739348), and LY2886721 (NCT01807026 and NCT01561430) have all exposed efficiency in decreasing the production of Aβ by up to 80–90% in the cerebrospinal fluid (CSF) in humans. None of inhibitors of β-secretase have touched the market so far [37–40].

Inhibitors and modulators of γ-secretase

In the final stage of amyloidogenesis, γ-secretase complex is responsible for the production of Aβ(1–40) and Aβ(1–42). Inhibition of γ-secretase was firstly proposed strategy for the management of Alzheimer’s disease but the substrate promiscuity shows equal issues facing γ-secretase inhibitors. γ-secretase proposed to target the Notch protein which is responsible for the regulation of cell proliferation, development, differentiation and cellular communication but off target secondary effects are major concern [41–43].

Semagacestat (LY450139) named γ-secretase inhibitor reduces the Aβ level in the blood and in cerebrospinal fluid [44]. The results obtained from the clinical study conducted on 3000 patients shows the major adverse effects like decrease cognition abilities and difficulty in the carry out daily living activities and elevated skin cancer incidence and increased risk of infection and weight loss. Another γ-secretase named avagacestat discontinued in the development stage due to lack of efficacy (NCT00810147, NCT00890890, NCT00810147, NCT01079819, [45–47]).

Several nonsteroidal anti-inflammatory drugs like indomethacin, ibuprofen, flurbiprofen, sulindac also decreases the Aβ(1–42) peptide levels in in-vivo and in in-vitro studies. Ibuprofen is a cyclooxygenase inhibitor while R-flurbiprofen (tarenflurbil) is not, so the reduction of Aβ(1–42) peptide levels is not associated with the COX inhibition. Unfortunately, in clinical trials tarenflurbil and ibuprofen does not shows efficacy for the treatment of Alzheimer’s disease. The idea of long term use of NSAID’s for the treatments of Alzheimer’s disease as NSAIDS reduces the Aβ peptide level in blood but negative results reported in the clinical studies that’s why this hypothesis requires further investigations [48, 49].

Clinical studies with 8-hydroxiquinolines compounds like clioquinol and PBT2 also conducted for the treatment of Alzheimer’s disease. The mechanism of action is yet established, but the expected MOA suggested that the increased levels of oxidative stress is due to the copper ions binding to Aβ, leading to metal-mediated generation of ROS (reactive oxygen species). It is proposed that the 8-hydroxiquinolines may prevent Aβ aggregation and restoring homeostasis in the cellular levels of copper and zinc ions. But after in clinical development these compounds failed due to lack of efficacy [50–52].

Agents that stimulate the removal of amyloid deposits and aggregates

Another possible treatment choice that is involved on the amyloidogenic pathway is to stimulate the existing amyloid aggregates clearance. To achieve this, three different approaches have been assessed.
4.2.5 Activation of enzymes that destroy amyloid plaques

Amyloid plaques are destroyed by various proteases comprising neprilysin, IDE, plasmin, angiotensin converting enzyme, endothelin converting enzyme, and metalloproteinases. Levels of protein these enzymes reduces in AD, that promotes accumulation and formation of Aβ. Despite being an attractive approach for forming disease-modifying medicine, no compounds with this MOA have ever entered advanced clinical development because of lack of specificity.

4.2.6 Modulation of β-amyloid transport between the brain and the peripheral circulation

Transport of Aβ between the circulation of CNS and peripheral is controlled by: (i) apolipoproteins (e.g., Aβ might be transported from the blood to the brain when it is bound to APOE); (ii) low-density lipoprotein receptor-related protein (LRP-1), that enhances Aβ discharge from the brain to the blood; (iii) receptor for progressive glycation end products (RAGE), that enables the Aβ transport across the blood-brain barrier (BBB) [53, 54].

Any treatment goal, that is determined on this mechanism, is to decrease the load of cerebral amyloid by trying to control Aβ to the peripheral circulation. To this end, a different number of approaches have been suggested, particularly the administration of LRP-1 peripherally. Though, the only drug candidates that have entered the clinical phase are the RAGE inhibitors.

4.2.7 Antiamyloid immunotherapy

4.2.7.1 Active immunotherapy

Immunotherapy approach designed to stimulate clearance of Aβ with the aimed of decreasing load of amyloid load in AD. Active immunization (vaccination) with either Aβ(1–42) (main form found in senile plaques) or other synthetic fragments has been positively assessed in transgenic mouse models of AD. Human tests were primarily hopeful; though first-generation vaccine (AN1792) treatment has shown major adverse events which results to the phase II trials cessation. AN1792 contained of a synthetic full-length Aβ(1–42) peptide with a QS-21 adjuvant. Because of a T cell-mediated autoimmune response, 6% of patients have established inflammation in brain that ended up being aseptic meningoencephalitis [55].

Second-generation vaccines were planned utilizing a limited portion of Aβ(1–6) peptide in an try to inhibit nonspecific immune response seen with the full-length vaccine. Novartis designed CAD 106, was the first second-generation vaccine which moved to development phase. Newly finished phase II trial have exposed a Aβ-specific antibody response in 75% of treated patients, without producing any side effect. Janssen developed ACC-001, has freshly finished two-phase II trials (NCT01284387 and NCT00479557) with an additional phase II trial still continuing (NCT01227564). Though, the pharmaceutical industry has canceled the ideas for this vaccine development. Further vaccines, comprising tetra-palmitoylated Aβ(1–15) re-formed in a liposome (ACI-24), MER5101 and AF205 are now in different phases of preclinical progression [56–58].

4.2.7.2 Passive immunization

It is the monoclonal or polyclonal antibodies administration directed against Aβ. This treatment contains intravenous administration of anti-Aβ antibodies to the
Alzheimer's Disease: An Insightful Review on the Future Trends of the Effective Therapeutics
DOI: http://dx.doi.org/10.5772/intechopen.102762

patient. The advantage of this approach is to match to active immunization is which the proinflammatory T cell-mediated immune response should not arise. Reports have shown that in transgenic animals passive immunization decreases the load of cerebral amyloid and recovers cognition, even when the amyloid plaque numbers are not suggestively decreased. This could be recognized to the soluble amyloid oligomers neutralization, that progressively identified to play an important role in the pathophysiology of AD.

Bapineuzumab and solanezumab are two monoclonal antibodies which are reach now present in advanced phase of development. Though, two phase III trials had failed in 2012 due to low effectiveness in patients with mild-to-moderate AD [59]. Both are humanized monoclonal antibodies against Aβ(1–6) and Aβ(12–28), respectively. In bapineuzumab, noteworthy decrease in brain amyloid plaques and phosphorylated Tau in cerebrospinal fluid was stated. Though, the treatment unsuccessful to give noteworthy developments of brain function. In a solanezumab trial, infusions of 400 mg of solanezumab or placebo were given for 80 weeks once a month in patients with mild-to-moderate AD. The outcomes recommended that solanezumab might recover cognition in mild AD; but statistical significance was not attained in study. Presently solanezumab present in phase III trials in patients with AD (NCT01127633 and NCT01900665) and in older persons who have common thinking and memory function but who might be at danger of AD developing in the future (NCT02008357, [60, 61]).

Crenezumab (MABT5102A) is a humanized monoclonal antibody that uses IgG4 backbone. In April 2014 a stage II trial to measure the safety and effectiveness in patients with mild-to-moderate AD (NCT01343966) was accomplished, while the outcomes are not yet openly accessible. The supreme stage II trial pointing to assess the safety and effectiveness of crenezumab in asymptomatic transporters of E280A autosomal-dominant mutation of PSEN1 initiated in November 2013 (NCT01998841).

Other monoclonal antibodies against Aβ established so far contain PF-04360365 (ponezumab) that targets the free carboxy terminal amino acids 33–40 of the Aβ peptide; MABT5102A, that binds to Aβ monomers, oligomers, and fibrils with similarly great affinity; GSK933776A, that is likewise to bapineuzumab in which it binds to the N-terminal Aβ(1–5). Additional, other passive immunotherapies typically in stage I clinical trial involve NI-101, SAR-228810, and BAN-2401 [58, 62].

4.2.8 Approaches focused on Tau proteins

In neurons Tau proteins are extremely soluble and abundant where they play a important role in stabilization of microtubule, mainly in axons [63]. Tau hyperphosphorylation resulting the insoluble paired helical filaments (PHF) development that form neurofibrillary tangles. The microtubule-binding capacity damage initiate destabilization of cytoskeleton, that ultimately develops neurodegeneration and neuronal death [64]. As a substitute to amyloidocentric strategies, this treatments goal to prevent the phosphorylation of Tau protein. Additional, microtubule-stabilizing drugs can be utilized as a disease-modifying approach in AD. In current years, immunomodulation was recommended as a feasible choice for stimulating operative Tau aggregates clearance [65].

4.2.9 Hyperphosphorylation of Tau inhibitors

All Tau proteins are a result of different splicing of a microtubule-associated protein Tau (MAPT) gene. Primary mechanism that controls Tau binding to microtubules is phosphorylation. The protein remains soluble under physiological circumstances; though, in this disease, pathological hyperphosphorylation of Tau
Alzheimer's Disease

compromises its regular functions [66, 67]. Imbalance between the catalytic activity of kinases and phosphatases occurs hyperphosphorylation. Enhanced expression of active forms of several kinases in the areas proximal to neurofibrillary tangles has been labeled in AD, comprising CDK5, GSK3β, Fyn, stress-activated protein kinases JNK and p38, and mitogen-activated protein kinases ERK1 and ERK2 [68]. Certain kinases promote continuation of tau phosphorylation in neurofibrillary tangles. Resulting, noteworthy research determinations have been dedicated to the kinase inhibitors development as a probable treatment approach for AD. For example, SP600125, a extensively utilized pan-JNK inhibitor, employs valuable effects on cognition and decreases neurodegeneration in an APP/PS1 transgenic mouse model of AD. It has been planned which precise inhibition of JNK3 can be adequate to carry comparable benefits as seen with SP600125 in rodent models. Human data in AD patients designate a positive correlation between the JNK3 and Aβ (1–42) levels in the brain. Moreover, JNK3 upregulation was distinguished in the CSF and was related with loss of memory. Consequently, inhibition of JNK3 remains a capable goal for future treatments [69–71].

4.2.10 Tau aggregation inhibitors

Tau hyperphosphorylation contribute to neurotoxicity detected in AD brain. Methylene blue dye derivatives have revealed certain potential Tau aggregates formation inhibition. Methylene blue disturbs the Tau aggregation, has the capability to prevent amyloid aggregation, recovers the effectiveness of mitochondrial electron transport chain, decreases oxidative stress, stops mitochondrial impairment, and is also an autophagy modulator. The first-generation molecule resulting from methylene blue (Rember) seemed to stabilize AD development in a clinical trial that continued 50 weeks. These outcomes encouraged investigators to form a next-generation form of methylene blue, TRx 0237. This agents is a purified derivative of methylene blue that not only prevents aggregation of Tau protein but also liquefies brain tau aggregates. Various trials are presently ongoing (NCT01626391, NCT01689233, NCT01689246, NCT01626378) to assess the possible effectiveness of this agent in AD [72, 73].

4.2.11 Stabilizers of microtubule

Stabilization of microtubule might possibly attain a comparable end-result as which seen with the Tau hyperphosphorylation inhibitors. Paclitaxel is a microtubule-stabilizing agents presently in utilize in the oncology arena. Inappropriately, this agents is unable of BBB crossing and its utilize is related with major adverse events, that limits its efficacy in AD. In addition to paclitaxel, other microtubule-stabilizing agents like TPI 287 have been measured as a probable AD remedy. TPI 287 is a derivative of taxane, also utilize in the treatment of cancer. TPI 287 alleviates the microtubules by binding to tubulin. NCT01966666 trial will estimate TPI-287 safety, pharmacokinetic possessions, and tolerability by intravenous infusion in mild-to-moderate AD.

Epothilone D is a microtubule-stabilizing agent that enhanced axonal transport, decrease axonal dystrophy, reduced Tau neuropathology, and decreased hippocampal loss of neuron; though, in 2013 drug development for AD was discontinued after an unsuccessful clinical trial. With respect to Tau, more research are essential in order to better understand the exact molecular mechanisms elaborate in neurotoxicity of Tau. Current research associating the neurotoxic profiles of different forms of Tau recommend which is a soluble form is probable the greatest toxic. Thus, future therapeutic approaches should be focused on aiming Tau soluble forms [74].
4.2.12 Anti-Tau immunotherapy

Just as with the immunotherapies aiming Aβ, both passive and active immunization approaches against Tau have been measured. It was established that decrease in formation of Tau aggregate and enhanced Tau oligomers clearance and insoluble aggregates could all be reached with either active or passive immunotherapies. In rodents, treatment with monoclonal antibodies directed against hyperphosphorylated Tau has results to improvements in cognition and was not connected with noteworthy side effects.

Axon neuroscience began a stage I trial in 2013 to estimate the safety and tolerability of AADvac-1, an active immunotherapy that contains synthetic peptide derived from the Tau sequence coupled to keyhole limpet hemocyanin; the precise molecular nature of the antigen has not been disclosed (NCT01850238 and NCT02031198). AADvac-1 uses aluminum hydroxide as an adjuvant. At the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, good preclinical safety profile was reported for the treatment period of up to 6 months in rats, rabbits, and dogs. These initial outcomes are hopeful and it remains to be seen whether AADvac-1 will prove satisfactory safety and efficiency in patients [75, 76].

4.2.13 The cholinergic hypothesis

The hippocampus, the chief region of brain elaborate in memory processing, is influenced by modulation of cholinergic neurotransmitter. One of the well categorized irregularities linked with neurotransmitter deviations is the cholinergic neurons degeneration in the nucleus basalis of Meynert and the cholinergic inputs loss to the neocortex and hippocampus. Various studies reported reduced in choline acetyltransferase (ChAT), acetylcholine (ACh) release, as well as decreases in nicotinic and muscarinic receptors in the cerebral cortex and hippocampus of postmortem AD brains. Acetylcholinesterase inhibitors (AChEI), one of the only two classes of compounds that presently accepted for AD treatment, act by stimulating ACh bioavailability at the synapse. Inappropriately, none of these agents are proficient of withdrawing the course of AD nor of even noticeably reducing down the degree of disease development. Their clinical effect is basically palliative; though, their possible utilize in combination therapy with other disease-modifying agents should not be omitted [77, 78].

4.2.14 Altering the perception: AD as a metabolic disorder

As revealed by clinical study data and research articles that diabetes is a one of the key factor that leads to AD pathology and unfolds the close connection between insulin-deficient diabetes and cerebral amyloidosis. These data also suggests about insulin signaling impairments (both peripheral and central) is possibly be existing in both diseases. Hence, considering insulin hormone at the core, “type 3 diabetes” hypothesis of AD was developed, observing metabolic phenotypes into a coherent framework [79].

The most anticipated mechanisms for the development of AD due to diabetes could be: glucose toxicity, insulin resistance, oxidative stress, elevated levels of advanced glycation end products, and cytokine-mediated neuroinflammation. Recently, Clarke and colleagues demonstrated that neuroinflammatory cascades can be initiated by the administration of soluble hypothalamic Aβ oligomers that ultimately causes disturbances in peripheral glucose homeostasis. Tumor necrosis factor α (TNFα) may have a significant role during this process [80].

Rosiglitazone and pioglitazone are used as antidiabetic drugs, which regulate glucose homeostasis by increasing insulin sensitivity, reducing blood glucose levels,
and improving lipid metabolism. Both compounds have also been studied as potential therapeutics for AD treatment, with reported improvements in mitochondrial oxidative metabolism [81]. In animal models, pioglitazone modified various indices of brain aging but did not slow down the cognitive decline. Rosiglitazone and pioglitazone also induce the expression of peroxisome proliferator-activated receptor-γ co-activator 1 alpha (PGC-1α), a molecule that plays multiple roles in mitochondrial biogenesis, energy metabolism, and mitochondrial antioxidants expression. Previous studies have demonstrated that, in the human brain tissues, the expression of PGC-1α decreases with progression of AD dementia. Thus, PGC-1α upregulation may improve the mitochondrial energy metabolism and AD pathology [82–86].

In a small scale clinical trial on mild-to-moderate AD patients, it was found that pioglitazone enhances memory and cognition. On the other hand clinical trial (phase II) with larger group of patients (who did not possess an ApoE4 allele) were on treatment with rosiglitazone (6 months) shows improvement in memory retention and attention. However, similar study (phase III trial) using rosiglitazone failed to show efficacy in AD (NCT00550420). It is important to note that rosiglitazone was administered at much lower dosage than required to exert efficacious effects on AD pathophysiology in these trials, in rodent models of the disease. NCT00348140 recently completed clinical trial in which rosiglitazone was administrated in combination with AChEIs in patients with AD (mild-to-moderate) and until now no further outcome yet reported.

As a treatment possibility for AD, intranasal insulin have also been considered as it bypasses the BBB easily; adding the advantage of possibly minimum adverse events in peripheral tissues. Theoretically it is well established that direct delivery of insulin to the brain will activate cerebral insulin signaling leading to enhancements in memory processing resulting into neuroprotection. A recent ongoing clinical trial (with NCT017679090 is assessing long-term (12 months) efficacy of intranasal insulin (Humulin R U-100) among mild AD patients [87].

Also, it has been found that reduced plasma amylin concentrations may contribute in the progression of AD. As revealed by transgenic animal models of AD, amylin and pramlintide (amylin analog) reduced the brain Aβ levels and advances cognition. Interestingly, amylin inhibits β-secretase, whereas pramlintide did not [88].

5. Medicinal plants for the treatment of Alzheimer’s disease

Here is the number of herbal plants reported to might have anti-Alzheimer activity (Table 3).

6. Recent advances in the treatment of Alzheimer’s disease

In 2021 USFDA approved Aducanumab (marketed as Aduhelm) for the treatment of Alzheimer’s disease. It is an amyloid beta-directed antibody approved under the accelerated approval pathway based on reductioning amyloid β plaques observed in patients treated with this drug.

It was approved for medical use in the United States. Aducanumab has since been approved by the Ministry of Health and Prevention in the United Arab Emirates as of October 3, 2021, making it the second country in the world to approve the treatment.

Pharmacology-Mechanism of Action: Immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of
### Alzheimer’s Disease: An Insightful Review on the Future Trends of the Effective Therapeutics

DOI: [http://dx.doi.org/10.5772/intechopen.102762](http://dx.doi.org/10.5772/intechopen.102762)

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Work done</th>
<th>Plant used</th>
<th>Common name</th>
<th>Author</th>
<th>Year</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Effects of the hydroethanolic extract of <em>Lycopodium selago</em> L. on scopolamine-induced memory deficits in zebrafish</td>
<td><em>L. selago</em></td>
<td>Fir clubmoss</td>
<td>Valu et al.</td>
<td>2021</td>
<td>[89]</td>
</tr>
<tr>
<td>2.</td>
<td>Evaluation of traditional herb extract <em>Salvia officinalis</em> in treatment of Alzheimer’s disease</td>
<td><em>S. officinalis</em></td>
<td>Sage</td>
<td>Datta et al.</td>
<td>2020</td>
<td>[90]</td>
</tr>
<tr>
<td>3.</td>
<td>Protective effects of tenuifolin isolated from <em>Polygala tenuifolia</em> Wild roots on neuronal apoptosis and learning and memory deficits in mice with Alzheimer’s disease</td>
<td><em>P. tenuifolia</em></td>
<td>Yuan zhi</td>
<td>Wang et al.</td>
<td>2019</td>
<td>[91]</td>
</tr>
<tr>
<td>4.</td>
<td><em>Convolvulus pluricaulis</em> (Shankhapushpi) ameliorates human microtubule-associated protein tau (<em>hMAP</em>) induced neurotoxicity in Alzheimer’s disease <em>Drosophila</em> model</td>
<td><em>C. pluricaulis</em></td>
<td>Shankhapushpi</td>
<td>Kizhakke et al.</td>
<td>2019</td>
<td>[92]</td>
</tr>
<tr>
<td>5.</td>
<td><em>Malva parviflora</em> extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer’s disease by restoring microglial function via a PPAR-γ-dependent mechanism</td>
<td><em>M. parviflora</em></td>
<td>Cheeseweed</td>
<td>Jiménez et al.</td>
<td>2019</td>
<td>[93]</td>
</tr>
<tr>
<td>6.</td>
<td>Antioxidant, anti-Alzheimer and anti-parkinson activity of <em>Artemisia nilagirica</em> leaves with flowering tops</td>
<td><em>A. nilagirica</em></td>
<td>Indian wormwood</td>
<td>Pal and Pradeep</td>
<td>2018</td>
<td>[94]</td>
</tr>
<tr>
<td>7.</td>
<td>Antioxidant and anti-acetylcholinesterase activities of essential oils from garlic (<em>Allium sativum</em>) Bulbs</td>
<td><em>A. sativum</em></td>
<td>Garlic</td>
<td>Akinyemi et al.</td>
<td>2018</td>
<td>[95]</td>
</tr>
<tr>
<td>Sr. No.</td>
<td>Work done</td>
<td>Plant used</td>
<td>Common name</td>
<td>Author</td>
<td>Year</td>
<td>Ref.</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
<td>------------</td>
<td>-------------</td>
<td>--------</td>
<td>------</td>
<td>------</td>
</tr>
<tr>
<td>10.</td>
<td>Ameliorative effect of <em>Cleome gynandra</em> L. against scopolamine induced amnesia in mice</td>
<td>C. gynandra</td>
<td>Shonna cabbage</td>
<td>Manasa et al.</td>
<td>2017</td>
<td>[98]</td>
</tr>
<tr>
<td>11.</td>
<td>Evaluation of nootropic activity of green peas in mice</td>
<td><em>Pisum sativum</em></td>
<td>Green peas</td>
<td>Kaura et al.</td>
<td>2017</td>
<td>[99]</td>
</tr>
<tr>
<td>12.</td>
<td>Ameliorative effect of <em>Apium graveolens</em> Linn on scopolamine-induced amnesia mice</td>
<td><em>A. graveolens</em></td>
<td>Celery</td>
<td>Phetcharat et al.</td>
<td>2017</td>
<td>[100]</td>
</tr>
<tr>
<td>15.</td>
<td>Evaluation of nootropic activity of <em>Curcuma longa</em> leaves in diazepam and scopolamine-induced amnesic mice and rats</td>
<td><em>C. longa</em></td>
<td>Turmeric</td>
<td>Reddy et al.</td>
<td>2015</td>
<td>[103]</td>
</tr>
<tr>
<td>16.</td>
<td>Effect of ethanol seed extract of <em>Bauhinia purpurea</em> linn on cognition in scopolamine induced Alzheimer's disease rat's model</td>
<td><em>B. purpurea</em></td>
<td>Orchid tree</td>
<td>Nemalapalli et al.</td>
<td>2015</td>
<td>[104]</td>
</tr>
<tr>
<td>17.</td>
<td><em>Mori fructus</em> improves cognitive and neuronal dysfunction induced by beta-amyloid toxicity through the GSK-3β pathway in vitro and in vivo</td>
<td><em>M. fructus</em></td>
<td>Mora</td>
<td>Kim et al.</td>
<td>2015</td>
<td>[105]</td>
</tr>
<tr>
<td>18.</td>
<td>Anticholinesterase and antioxidant properties of aqueous extract of <em>Cola acuminata</em> seed</td>
<td><em>C. acuminata</em></td>
<td>Cola nut</td>
<td>Oboh et al.</td>
<td>2014</td>
<td>[106]</td>
</tr>
</tbody>
</table>
Alzheimer's Disease: An Insightful Review on the Future Trends of the Effective Therapeutics
DOI: http://dx.doi.org/10.5772/intechopen.102762

<table>
<thead>
<tr>
<th>Sr. No.</th>
<th>Work done</th>
<th>Plant used</th>
<th>Common name</th>
<th>Author</th>
<th>Year</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Antiamnesic activity of Syzygium cumini against scopolamine induced spatial memory impairments in rats</td>
<td><em>S. cumini</em></td>
<td>Jamun</td>
<td>Alikatte et al.</td>
<td>2012</td>
<td>[108]</td>
</tr>
<tr>
<td>21</td>
<td>Acetylcholine and memory-enhancing activity of Ficus racemosa bark</td>
<td><em>F. racemosa</em></td>
<td>Cluster fig</td>
<td>Faiyaz et al.</td>
<td>2011</td>
<td>[109]</td>
</tr>
<tr>
<td>22</td>
<td>Protective effect of Morinda citrifolia fruits on beta-amyloid (25–35) induced cognitive dysfunction in mice: an experimental and biochemical study</td>
<td><em>M. citrifolia</em></td>
<td>Noni</td>
<td>Muralidharan et al.</td>
<td>2010</td>
<td>[110]</td>
</tr>
</tbody>
</table>

Table 3. Plants studied in Alzheimer's disease.

![Figure 2.](image)

Drugs in clinical trials for treatment of Alzheimer's disease in 2021. In which the shape of icons shows the population involved in trials; the outer ring shows drugs in Phase I; the middle rings show drugs in Phase II; the innermost ring shows drugs in Phase III trials [16].
amyloid beta. The buildup of beta amyloid plaques in brain is crucial pathophysi-
ological hallmark of Alzheimer's disease.

**Dosage Form and Strength:** Aduhelm is a clear to opalescent and colorless to
yellow solution, accessible as: Injection: 170 mg/1.7 mL (100 mg/mL) in a single-
dose vial and 300 mg/3 mL (100 mg/mL) in a single-dose vial [111].

**Who should take this drug?**
It is suggested for mild cognitive impairment (MCI) or mild dementia stage of
Alzheimer’s disease [112, 113].

6.1 Novel compound under investigation

Here is the figure that shows the agents which is in developing stage involve in
the trials for the management of Alzheimer’s disease. Most of agents in the trial
target disease modification [114] (Figure 2).

In which the shape of icons shows the population involve in trials; the outer ring
shows drugs in phase I; the middle rings shows drugs in phase II; the inner most
ring shows drugs in phase III trials [115].

7. Conclusion

Alzheimer’s disease is serious brain disorder, at present there is no cure for this
disease but currently it can be controlled by using a drugs which symptomatically
treat AD. AChE inhibitors are the first approved anti-AD drugs by the FDA, and
they are also the first and the most useful drug used in the clinical treatment of AD.
But now few of drugs also approved by USFDA in 2021 for the treatment of AD
and few also in the trial phase. Results from clinical studies have shown different
new drugs in pipeline and various novel approaches may also beneficial for treating AD. Interests in the utilization of different herbal products also increase day by
day. This study provides the details about recent advancement the medicinal plants
against the Alzheimer’s disease. Availability of these new medicinal plants for AD
will further increase the treatment options and thus provide a significant benefit to
patients who remain uncontrollable to existing therapy.

**Author details**

Afreen Hashmi*, Vivek Srivastava, Syed Abul Kalam and Devesh Kumar Mishra
Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow, India

*Address all correspondence to: afreenhashmimgip@gmail.com

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
References


treatment considerations of donepezil in severe Alzheimer’s disease. CNS Neuroscience & Therapeutics. 2018; 24(10):876-888


placebo-controlled phase III study. Dementia and Geriatric Cognitive Disorders. 2010;30(2):131-146


Chapter 4

MicroRNAs as Future Treatment Tools and Diagnostic Biomarkers in Alzheimer’s Disease

Heena Chauhan, Pawan Gupta and Bhagawati Saxena

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder and is considered to be the most common form of dementia. This disorder is characterized by the formation of amyloid β (Aβ) plaques, neurofibrillary tangles, and alterations in synaptic function, all of which cause memory loss and behavioral disturbances. Despite the high prevalence of AD, effective therapeutic and diagnostic tools remain unavailable. MicroRNAs (miRNAs, miRs) are regulatory non-coding RNAs that target mRNAs. MiRNAs are involved in the regulation of the expressions of APP and BACE1, Aβ clearance, and the formation of neuro-fibrillary tangles. Furthermore, there are evidences that show alteration in the expression of several miRs in AD. MicroRNA is emerging as a biomarker because they have high specificity and, efficiency, and can be detected in biological fluids such as cerebrospinal fluid, tear, urine, blood. Moreover, miRNAs may be acquired and measured easily by utilizing real-time PCR, next-generation sequencing, or microarray. These techniques are cost-effective in comparison with imaging techniques such as magnetic resonance imaging, positron emission tomography. These features make miRNAs viable therapeutic as well as diagnostic tools in the treatment of AD. This review covers the regulatory function of miRNAs in AD, as well as their prospective applications as diagnostic biomarkers.

Keywords: Alzheimer’s disease, dementia, pathogenesis, microRNAs, diagnosis, biomarker

1. Introduction

Alzheimer’s disease (AD) is a neurodegenerative disorder and is considered to be the most common form of dementia that majorly occurs in aged persons although a familial form of AD can occur in the younger population. Familial (early-onset) AD occurs due to mutations in the amyloid precursor protein (APP), presenilin 1, and presenilin 2 genes [1]. However, further identification of tau gene mutations in familial frontotemporal dementia (FTD) with chromosome 17 has shown a clear relationship between tau malfunction and dementia [2]. These findings show that AD and FTD are related in a hereditary spectrum of degenerative brain illnesses in which tau appears to play a key role [3]. Clinical manifestations of AD include a slow and persistent deterioration in memory, executive functions, and the capacity to carry out daily activities [4, 5]. Dementia affects around 36.5 million individuals worldwide in 2010. Every 20 years, the number of dementia cases is expected
Alzheimer's Disease

to roughly quadruple, reaching 65.7 million in 2030 and 115.4 million in 2050. AD is accounting for the preponderance of these dementia instances, accounting for 60–80% of all dementia cases [6]. Every year, an estimated 5–7 million new instances of AD are diagnosed in the elderly population [7]. In 2020, overall healthcare expenditures for AD treatment are predicted to be $305 billion, with expenditure expected to rise to more than $1 trillion as the population ages [8]. Even moderate developments in preventative and therapeutic techniques that postpone the initiation and advancement of AD can considerably lower the illness's worldwide impact [9].

2. Pathophysiology involved in AD

The scientific field dedicated for understanding the mechanisms involved in the progression of AD and developing relevant therapeutics is vast. Pathologically hallmarks of AD include the extra-neuronal clustering of Aβ plaques and the formation of intraneuronal neurofibrillary tangles (NFTs) which result in neuronal synaptic dysfunction [10, 11]. Aβ plaques formation is found in basal ganglia, amygdala, diencephalon, hippocampus, temporal and later it is found in the brain stem, cerebellar cortex and mesencephalon. The high levels of Aβ plaques are responsible for tau formation in the entorhinal, transentorhinal as well as locus coeruleus areas of the brain. It spreads to the hippocampus and neocortex in the critical stage [12].

Aβ plaque is formed from proteolysis of APP followed by two pathways (1) non-amyloidogenic pathway (physiological pathway), (2) amyloidogenic pathway (Figure 1). APP is a transmembrane glycoprotein whose a large portion toward the cytoplasm and a short portion inside the lumen. The non-amyloidogenic pathway prevents to the formation of toxic Aβ as APP is first cleaved by α-secretase and generates soluble fragments sAPPα and C83. These further cleaved by γ-secretase and produced non-toxic p3 and APP Intracellular Domain (AICD). On the other hand, the amyloidogenic pathway, neurotoxic Aβ formed through cleavage of APP by β-secretase (BACE1) followed by γ-secretase and formed sAPPβ, C99, Aβ, and AICD. These fragments are functionally active and influence or modulate signaling proteins [13]. Aβ oligomerization led to the formation of senile plaques and blockage the nerve transmission. There are mainly two types of Aβ isoforms soluble Aβ40 and insoluble Aβ42. The latter Aβ is more prone to aggregate and high concentration found in AD patients [14, 15]. The Aβ polymers aggregation results in blockage of ion channel, decreased energy metabolism, alteration in calcium homeostasis, diminish glucose regulation, and increases mitochondrial stress level, which further plays role in abnormality in neuronal health and causes neuronal death [12, 16]. Moreover, the AICD acts differently according to its generating pathways. The AICD from non-amyloidogenic pathways is degrading rapidly, but in the case of the amyloidogenic pathway, AICD behaves as a regulator for other genes [17].

Intra-neuronal deposition of NFTs are another pathophysiological hallmark of AD. NFTs were predominantly consisted of hyper-phosphorylated tau due to imbalance between phosphorylation and de-phosphorylation of tau [18]. Kinases are involved in the phosphorylation of tau protein, while phosphatases remove the phosphate residues. Tau proteins are microtubule-associated proteins that help vesicle transportation by stabilizing the microtubule. Microtubules are essential for axonal transport, neuronal structure, and neural plasticity [19]. Heavily phosphorylated tau may lose its capacity to stabilize itself and begin to self-form NFTs. Neurons cannot operate correctly without a full system of microtubules, and they eventually die. Tauopathies are considered to be an indicator of the severity of AD [20].
3. MicroRNA

MicroRNA (miRNA/miR) is a kind of non-coding RNA that has 22–23 nucleotides. They regulate gene expression by interacting with the 3′-untranslated region (3′UTR) of mRNA. Thus, miRNA inhibits translation or destroys the targeted mRNA as a result of this event [21, 22]. Biogenesis of miRNA occurs with both canonical pathways as well as non-canonical pathways. However, miRNAs are processed dominantly by the canonical biogenesis pathway [23]. The detailed process of miRNA biogenesis by canonical pathway is illustrated in Figure 2. RNA polymerase II in the nucleus transcribed miRNAs gene to primary miRNAs (pri-miRNAs). In collaboration with Pasha/DGCR8, the RNase III enzyme, Drosha converts these pri-miRNAs into precursor miRNAs (pre-miRNAs) and then these pre-miRNAs are transported to the cytoplasm by Exportin 5 [24, 25]. These pre-miRNAs are of approximately 70 nucleotides in a hairpin structure. Pre-miRNAs features a hairpin loop structure that is identified by dicer present in the cytoplasm for cleavage, resulting in the formation of mature miRNAs which is a double-stranded miRNA duplex [25]. The miRNA-induced silencing complex (miRISC) is formed when one of these strands of the mature duplex is loaded onto a member of the Argonaute (Ago) family of proteins, whereas the other strand of the mature duplex is normally destroyed. RISCs mediate gene silencing by recognizing the 3′ untranslating region (3′ UTR) of target mRNA [24, 25].
4. Association of microRNAs and Alzheimer’s disease

Pathologically, AD is generated by impaired metabolism of Aβ and the imbalance between the hyper-phosphorylated and de-phosphorylated forms of tau. Although these clinical-pathological features of AD are extensively established, therapies aiming at lowering synthesis or eliminating misfolded proteins are very limited [21]. Only four medicines, including three cholinesterase inhibitors (donepezil, rivastigmine, and galanthamine) and the glutamate regulator memantine, were licensed by the US Food and Drug Administration (FDA) for the treatment of cognitive impairment and dysfunction in symptomatic AD until June 2021. These symptomatic therapies can only delay rather than stop disease development [26, 27]. On June 7, 2021, Aducanumab, the first targeted Alzheimer’s therapy was approved by the FDA to treat patients with AD [27].

Thus, a different approach has centred on genetics, with several genes encoding proteins in central nervous system (CNS) offered as candidates to explain AD etiology [21]. Earlier studies showed miRNA play role in the elaborating different types of pathogenic diseases including cardiovascular, cancer, and neurological disorders [28, 29]. Numbers of studies show the involvement of miRNAs in the pathogenesis and their therapeutic potential in various neurodegenerative diseases including AD, Huntington’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Prion diseases [30, 31]. AD study indicates that miRNA may be helpful for the regulation of genes, expressions of proteins, and changes in phenotype in human diseases. Some research studies show the abnormal regulation of miRNA-dependent genes which are responsible for the formation and deposition of Aβ plaques as well as NFTs and consequently neuronal-degeneration [32–35]. The focus of this review is the implication of the miRNAs in the two most well-recognized theories of AD pathogenesis: the Aβ hypothesis (Figure 3) and the tau hypothesis (Figure 4).
Figure 3.
A schematic diagram of the Aβ hypothesis in AD pathogenesis and involvement of miRNA in each stage. The amyloid beta is produced as a result of processing the APP (amyloid precursor protein) by a sequential enzyme digested by BACE1 and γ-secretase generate imbalance between the clearance and production of Aβ which is the key factor of AD.

Figure 4.
The imbalance between the hyper-phosphorylated and de-phosphorylated processes of Tau could lead to the formation of NFTs. The miRNAs involved in the phosphorylated and de-phosphorylated processes play a role in AD pathogenesis.
Alzheimer’s Disease

4.1 MicroRNAs involved in the regulation of APP expression

Although APP regulation is challenging, the research of regulatory processes indicate the prognosis of Alzheimer’s patients (Figure 3). Some scientific evidence shows that miR-106b regulates APP expression by binding on the 3’UTR region of APP [33]. The miR-101 [36], miR-16 [37], and miR-153 [38] are found APP negative regulators in in-vitro studies as well as in-vivo studies.

4.2 MicroRNAs involved in the regulation of BACE1 expression

It has been found that BACE-1 expression and activity are regulated by some miRNAs like the miR-29 family. BACE-1 expression level is increased with decreased expression of miR29a/b1 in sporadic AD brain. Moreover, it was also validated that low-level expression of miR29a/b1 is responsible for the pathogenesis of AD by promoting the production of Aβ plaques [39]. Another study found that downregulation of BACE1 is found in a cell line (SH-SY5Y) with overexpression of miR-29c via binding of BACE-13’ UTR [40]. Another study revealed that miR-107 regulates the expression of BACE1 in cell culture by binding the 3’UTR of BACE1 [41]. It was demonstrated that the BACE1 mRNA level was negatively affected by miR-107. Therefore, miR-107 could be a potential drug target [42] as it prevents the Aβ induced neurotoxicity and blood barrier dysfunction [43]. Certain miRNAs which are negative regulators of BACE1 expression by binding with 3’ UTR of BACE1 include miR-298/328 [44], miR-135a [45], miR135b [46], miR-186 [47], miR-195 [48], miR-200b [45], and miR-339-5P (Figure 3) [49].

4.3 Role of MicroRNAs in Aβ clearance

The deposition of Aβ occurred due to an imbalance between production and clearance of Aβ. Several studies show that certain microRNAs are involved in the clearance of Aβ. The upregulation of miR-128 can alter the Aβ clearance by targeting the lysosomal enzyme system in monocytes of AD sporadic patients. The breakdown of Aβ plaque in Alzheimer’s patients improves when miR-128 is blocked in monocytes [50]. In addition, miR-34a was also involved in digesting the Aβ, thus improving the clearance of overexpressed Aβ [51]. miR-155, 154, 200b, 27b, 128 immune-related microRNA allegedly contribute to the process of Aβ clearance mediated by blood-derived monocytes (BDMs) when expressed variably in the CCL2/CCR2 (chemokine/chemokine receptor) axis [52]. miR-302 may attenuate Aβ induced neuronal toxicity in the brain of Alzheimer’s patients via PTEN/ AKT/ Nrf2/Ho-1 pathway. miR-137 may reduced Aβ induced toxicity of neurons with the help of NF-κβ by TNFAIP1 expression repressing in N2a cells [53].

4.4 MicroRNAs targeting neurofibrillary tangles

The expression levels of miR 26b [54], miR-125b [55, 56], miR-138 [57], and miR-146a [58] have been shown to be considerably up-regulated while miR-132/212 down-regulated [59] in Alzheimer’s patients. Overexpression of miR-125b inhibited the two phosphatases i.e., PPP1CA and DUSP6 which further causes tau hyperphosphorylation while kinase expression/activity and tau phosphorylation were reduced when miR-125b was inhibited [55]. miR-146a was discovered to specifically target the coiled-coil containing protein kinase1 (ROCK1) in brain cells, and inhibiting ROCK1 might cause aberrant tau phosphorylation [58]. Reports showed that miR-138 was found to promote tau phosphorylation via directly targeting the retinoic acid receptor alpha (RARA)/ glycogen synthase kinase-3b (GSK-3b) pathway in HEK293/tau and N2a/APP cells [57].
The increased levels of miR-26b in post-mitotic neurons led to the pathophysiology of AD via cell cycle entrance, tau hyper-phosphorylation, and death [54] (Figure 4).

5. MicroRNAs as possible treatment tools in Alzheimer’s disease

The usage of miRNA in the treatment of the disorder is developing fast. In 2018, the FDA accepted the primary miRNA-founded therapy for the cure of the infrequent progressive polyneuropathy produced by hereditary transthyretin-mediated amyloidosis (hATTR) known as amyloid polyneuropathy [60]. The fact that miRNAs alter (or control) the expression of potential genes in AD has prompted researchers to pursue miRNA-based therapeutic options. The treatment modifications of miRNA are carried out in two different ways: first, the functioning of miRNAs is suppressed by oligonucleotides that target miRNAs are known as antagonirs while in a second way, synthetic oligonucleotides are used which plays the same role as endogenous miRNA (act as miRNA mimics) [61, 62]. Thus, a miRNA mimetic or antagonist could be evaluated as a treatment tool. It was also observed that increased miRNA expression can counter the accumulation of Aβ and tau in cell and animal models of AD. In transgenic mouse model, the family of miR-200 (miR-200b and miR-200c) were recognized as Aβ secretion regulators by modulating mTOR in primary type of neurons [63–65]. The same effect of down-regulation in Aβ production was seen after miR-330 upregulation in mice model of AD by activating the MAPK pathway [66]. In in-vitro AD model, inhibition of Aβ accumulation was observed by miR-15b by targeting enzyme BACE1 and NF-kB signaling [67]. Similarly, in-vitro studies suggested that miR-124 works as a basic regulating factor in process of AD by targeting BACE1 and controlling BACE1 gene expression [68]. To understand the contribution of miR-124 in the pathogenesis of AD, the brain tissues of 35 cases of sporadic AD and control subjects were analyzed for miR-124 expression by the qRT-PCR technique. The reduction in the level of miR-124 expression was seen in AD brain tissues with comparison to the control group. In addition, inhibition of miR-124 significantly increased BACE1 levels in human neuroblastoma cells (SH-SY5Y), while miR-124 overexpression significantly suppressed BACE1 [69]. MiR-219 was shown to be downregulated in severe primary age-related tau pathology as evaluated by the RT-qPCR study. In addition, it was shown in the Drosophila model (which produces human tau) that the reduction of miR-219 increases tau toxicity, while the overexpression of miR-219 partially reverses this effect [70]. In in-vivo studies for cognitive capacity in SAMP8 mice, it was found that the miR-214-3p suppresses the autophagy and apoptosis of hippocampus neurons in sporadic Alzheimer's disease (SAD) [71]. It was also found that miR-let-7f-5p had anti-apoptotic and protective effect in Aβ induced neurotoxicity on grafted mesenchymal stem cells by targeting caspase-3 in AD model [72]. These findings suggested that miR-214-3p and let-7f-5p are having anti-apoptotic activity and increase the cell viability of neurons, therefore, it can be therapeutically important [71, 72]. One literature reported that NF-kB was inactivated by upregulation of PPAR-γ in mouse cortical neurons and Neuro2a cells. MiR-128 targeted the PPAR-γ and by targeting PPAR-gamma reduced the Aβ mediated cytotoxicity in the studies [73]. It was observed that overexpression of both miR-125b [55] and miR-146a [58] stimulates the apoptosis of neuron and tau phosphorylation in cellular and molecular AD models. In recent years many chemicals are studied that can affect miRNAs pharmacologically. Anti-inflammatory medications may be effective in preventing the course of AD through modulating miRNAs. Additionally, naturally obtained compounds are recognized for their possible effect as neuroprotective agents in AD, like resveratrol [74] and osthole [75], which appear to be effective by modulating a
specific type of miRNA and activate processes like autophagy and neuronal regeneration. Exosomes, tiny vesicles generated by neurons and glial cells, may also be used as therapies to give miRNAs and/or short interfering RNA (siRNA) to patients, according to new research. Multitargeted treatment methods, such as the use of acetylcholinesterase (AChE) inhibitors in conjunction with the manipulation of certain miRNAs, are also being investigated. Approaching miRNAs as therapeutic targets has two major drawbacks: (1) their ability to control several transcripts (up to hundreds) at once, and (2) the difficulty of achieving effective miRNA delivery.

6. MicroRNAs as possible diagnostic biomarkers in Alzheimer’s disease

AD is categorized, according to biochemical and clinical changes, into three different stages: pre-clinical i.e., early asymptomatic, mild cognitive impairment (MCI), and eventual dementia [76]. The majority of currently known biomarkers and approaches are focused on the late stages of the illness and may be categorized as follows: (1) neuropsychological tests, (2) neuroimaging techniques, and (3) protein biomarkers in the cerebrospinal fluid (CSF) [25]. Neuropsychological tests include cognitive assessments such as the Mini-Mental State Examination (MMSE) for early diagnosis to track cognitive changes over time and quantify the severity of cognitive impairment; however, this method is limited by factors such as the patient’s familiarity with the test and their educational attainment, which limits its sensitivity and specificity [77]. Neuroimaging examinations include fluorodeoxyglucose (FDG)-positron emission tomography (PET) and magnetic resonance imaging (MRI) for monitoring functional abnormalities as well as pathophysiological alterations such as medial temporal lobe atrophy and metabolic problems that can develop without evident cognitive impairment. Though this approach is viable, it has significant time and expense constraints. There are just a few laboratories that provide neuroimaging examinations. As a result, only a limited proportion of patients have access to neuroimaging [78]. Currently, protein biomarkers are the best biomarkers for monitoring AD and clinical research. They include Aβ1–40, Aβ1–4, phosphorylated tau (ptau), and total tau (t-tau) proteins in the CSF. However, a lumbar puncture is required to get CSF, which is invasive and not well tolerated by patients [78]. The identification of disease-causing genes is also a viable option. Simple, efficient, and inexpensive biomarkers for AD diagnosis are still lacking, especially in the early stages of the illness [25]. Several pieces of literature have found that particular miRNA species found in the biofluid of Alzheimer’s patients correlate with clinical alterations [22, 79–81]. Thus, miRNA emerges as a potential biomarker for initial diagnosis of AD as they are present in circulatory fluids which include CSF, seminal fluid, peritoneal fluid, amniotic fluid, pleural fluid, bronchial secretions seminal fluid, serum, plasma, and various other biological fluids [82, 83]. Circulatory miRNAs are a possible diagnostic biomarker for the illness because of their consistency and large quantity. miRNAs are when enwrapped in liposomes or attached to lipoproteins in the CSF, serum, or plasma, they are more stable and may endure harsh environmental conditions [84]. Furthermore, miRNAs may be acquired and measured with ease utilizing real-time PCR, next-generation sequencing (NGS), or microarray. Bio-molecules found in biological fluids such as CSF, tear, urine, and blood are being studied for their possible role in detecting disease progression in Alzheimer’s patients. According to previous research, miRNA is a modulator of the pathogenic state exhibited in AD [85]. Several miRNAs like miR-26b [54], miR-34a/c, miR125b, miR-210, and miR-146b are shown to change in blood and brain in Alzheimer’s patients, although the direction of changes is not always consistent between both
<table>
<thead>
<tr>
<th>Target</th>
<th>miRNA</th>
<th>Function</th>
<th>Bio-fluids</th>
<th>Upregulation (Up) or Downregulation (Down)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>APP</td>
<td>miR-106b</td>
<td>Regulate APP expression</td>
<td>Serum</td>
<td>Up</td>
<td>[33, 88, 89]</td>
</tr>
<tr>
<td></td>
<td>miR-101</td>
<td>Negative regulator of APP expression</td>
<td>Serum</td>
<td>Up</td>
<td>[36, 89, 90]</td>
</tr>
<tr>
<td></td>
<td>miR-16</td>
<td>Decreased expression of miR-16 lead to accumulation of APP protein in AD</td>
<td>Blood</td>
<td>Up</td>
<td>[37, 91]</td>
</tr>
<tr>
<td>ADAM10</td>
<td>miR-23a</td>
<td>Non-amyloidogenic APP processing</td>
<td>Serum</td>
<td>Up</td>
<td>[92, 93]</td>
</tr>
<tr>
<td></td>
<td>miR-107</td>
<td></td>
<td>Plasma</td>
<td>Down</td>
<td>[41, 94]</td>
</tr>
<tr>
<td></td>
<td>miR-451</td>
<td></td>
<td>Plasma-derived extracellular vesicles</td>
<td>Down</td>
<td>[93, 95]</td>
</tr>
<tr>
<td>BACE1</td>
<td>miR-9</td>
<td>TNF-α, ephrin-A2 and APP cleavage</td>
<td>CSF exosomes</td>
<td>Up</td>
<td>[96–99]</td>
</tr>
<tr>
<td></td>
<td>miR-107</td>
<td></td>
<td>Serum</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>miR-29a</td>
<td></td>
<td>Plasma</td>
<td>Down</td>
<td>[41, 94]</td>
</tr>
<tr>
<td></td>
<td>miR-29b</td>
<td></td>
<td>Serum</td>
<td>Up</td>
<td>[39, 96, 100]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CSF</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Serum</td>
<td>Up</td>
<td>[39, 96, 101]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CSF</td>
<td>Down</td>
<td></td>
</tr>
<tr>
<td>BDNF</td>
<td>miR-206</td>
<td>Growth factor involved in synapse maturation</td>
<td>Serum and plasma</td>
<td>Up</td>
<td>[102–104]</td>
</tr>
<tr>
<td>CREB1</td>
<td>miR-134</td>
<td>Transcription factor involved in synaptic plasticity</td>
<td>Plasma</td>
<td>Up</td>
<td>[105, 106]</td>
</tr>
<tr>
<td>DLG4</td>
<td>miR-125a</td>
<td>Scaffold protein (PSD-95)</td>
<td>CSF and Serum</td>
<td>Up</td>
<td>[107, 108]</td>
</tr>
<tr>
<td>DPYS2</td>
<td>miR-181c</td>
<td>Axon guidance (CRMP-2)</td>
<td>Plasma</td>
<td>Up</td>
<td>[86, 98, 109]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Serum</td>
<td>Down</td>
<td>[96]</td>
</tr>
<tr>
<td>EFNA3</td>
<td>miR-210</td>
<td>(Ephrin-A3) Axon guidance</td>
<td>Plasma</td>
<td>Up</td>
<td>[86, 110]</td>
</tr>
<tr>
<td>Target</td>
<td>miRNA</td>
<td>Function</td>
<td>Bio-fluids</td>
<td>Upregulation (Up) or Downregulation (Down)</td>
<td>References</td>
</tr>
<tr>
<td>---------</td>
<td>---------</td>
<td>-----------------------------------</td>
<td>------------</td>
<td>-------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>GRIA1</td>
<td>miR-137</td>
<td>Synaptic transmission</td>
<td>Serum</td>
<td>Down</td>
<td>[96, 111]</td>
</tr>
<tr>
<td></td>
<td>miR-501</td>
<td></td>
<td>Serum</td>
<td>Down</td>
<td>[78, 112]</td>
</tr>
<tr>
<td>GRIA2</td>
<td>miR-181a</td>
<td>Neurotransmitter release</td>
<td>Blood</td>
<td>Up</td>
<td>[113, 114]</td>
</tr>
<tr>
<td>GRIN2A</td>
<td>miR-125b</td>
<td>Synaptic transmission</td>
<td>CSF and Serum</td>
<td>Down</td>
<td>[115-117]</td>
</tr>
<tr>
<td>GRIN2B</td>
<td>miR-34a</td>
<td>Synaptic transmission</td>
<td>Plasma</td>
<td>Up</td>
<td>[101, 118, 119]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CSF</td>
<td>Down</td>
<td></td>
</tr>
<tr>
<td>IGF1</td>
<td>miR-26b</td>
<td>Growth factor involved in synapse maturation</td>
<td>Serum</td>
<td>Up</td>
<td>[116, 120, 121]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Blood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MME</td>
<td>miR-26b</td>
<td>Neurite outgrowth</td>
<td>Serum</td>
<td>Up</td>
<td>[116, 121, 122]</td>
</tr>
<tr>
<td>(NEP)</td>
<td></td>
<td></td>
<td>Blood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SYN</td>
<td>miR-106b</td>
<td>Inhibit tau phosphorylation</td>
<td>Serum</td>
<td>Up</td>
<td>[88, 89, 123]</td>
</tr>
<tr>
<td>STIM2</td>
<td>miR-128</td>
<td>NMDA-evoked intracellular Ca²⁺</td>
<td>Plasma</td>
<td>Up</td>
<td>[105, 124, 125]</td>
</tr>
<tr>
<td>SIRT1</td>
<td>miR-132</td>
<td>Acetylation of substrates related to learning and memory</td>
<td>Serum</td>
<td>Dow</td>
<td>[93, 102]</td>
</tr>
<tr>
<td>SYT1</td>
<td>miR-146a</td>
<td>Trafficking/neurotransmitter release</td>
<td>Blood</td>
<td>Up</td>
<td>[21, 113, 126]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>CSF and plasma</td>
<td>Down</td>
<td>[101]</td>
</tr>
<tr>
<td>TMOD2</td>
<td>miR-191</td>
<td>Actin filament organization</td>
<td>Plasma</td>
<td>Down</td>
<td>[127, 128]</td>
</tr>
<tr>
<td>VAMP2</td>
<td>miR-34c</td>
<td>Neurotransmitter release Vesicle</td>
<td>Plasma</td>
<td>Up</td>
<td>[129, 130]</td>
</tr>
</tbody>
</table>

Table 1.
Changes in the level of MiRNAs in the blood, plasma/serum and cerebral-spinal fluid (CSF) of AD patients with their targets and functions.
miRNA sources [22, 86]. Furthermore, miRNA isolated from Alzheimer’s patients’ blood plasma and serum including miR-545-3p, miR-107, miR-15b-5p, miR-191-5p has been expected as potential AD biomarkers [22]. MiR-455-3p has emerged as a possible AD biomarker since growing levels in serum are commensurate with levels in AD brains, fibroblasts, lymphocytes, and even AD transgenic models [87]. This emerges the need to further explore the potential of a single miRNA to identify prodromal AD. A panel of miRNAs implicated in pathological processes underlying AD, such as neuroinflammation, has emerged as a diagnostic tool for AD prediction. While much work is being done on miRNA-based biomarkers for AD, few studies in the area have looked at the link between AD biomarkers and synaptic function modulation. Table 1 summarizes the most important findings in synaptic-related miRNAs obtained from circulating biofluids of AD patients and their potential value as biomarkers. The majority of studies have been done in blood samples, including serum and plasma, indicating a desire to investigate less invasive biomarkers. Certain studies reported earlier demonstrated that reproducibility between studies might be challenging even when miRNAs are obtained from the same sample source. As an example, the drop in miR-132 in serum from mild cognitive impairment (MCI) and AD patients [102, 107], has been replicated in plasma sample [131], although Sheinerman and team found an increase in MCI individuals [105], MiR-132, along with miR-206, which is similarly downregulated in MCI serum, has been proposed as part of a serum-based signature for MCI identification [102]. The adoption of miRNA-based signatures, which take into account the simultaneous modification of many miRNAs, can result in greater accuracy, sensitivity, and specificity values, which could be beneficial for future diagnostic tools. Another signature based on serum-miRNA levels, including synaptic-related miR-23a, miR-29a, and miR-125b has shown promising results in distinguishing Alzheimer’s patients from healthy cognitive controls (HCC) [92]. Although results are inconsistent between researches, the diagnostic usefulness of the miR-29a/b family has been examined in serum and CSF [39, 92, 96, 100, 132]. The modification of these miRNAs in biological fluids during AD pathology appears to be obvious. MiR-125b and miR-23a, on the other hand, have continuously increased in serum, demonstrating a strong ability to differentiate between AD and control participants [92, 115]. MiR-125b’s potential has also been investigated in CSF, where it has subsequently been offered as a specialized tool [116]. As previously reported, an increase in associated miR-125a levels has been seen in CSF from AD patients, suggesting that it might be used as a biomarker [100, 107]. Limited literature has looked at miRNA levels over time to see whether they might predict the development of MCI into AD. Beneficial diagnostic tool for classify MCI from AD include miR-206 [103], miR-146a, and miR-181a [113], miR-181c [88, 92], miR-181a and miR-181c [105], miR-92a-3p, and miR-210-3p [86], miR-107 [133].

The potential utility and benefits of miRNAs as early biomarkers for AD underscore the urgent need for protocol standardization as a critical tool for accelerating development in generating more accurate findings and bringing breakthroughs to the clinics. Molecular diagnostics companies like DiamiR are already developing and commercializing miRNA-based technologies, demonstrating the progress made in the field and the real possibilities of using miRNAs as biomarkers for AD not only in screening and diagnosis but also as a useful tool for bettering the condition of clinical trial participants.

7. Conclusion

MiRNAs play an important role in the progression of AD. Alzheimer’s investigation indicates that miRNA may assist to gene regulation, protein-protein
expressions, and phenotypic changes in diseases condition and some indication shows that aberrant regulation of miRNA-dependent genes are related to some cellular and molecular events which are liable for Aβ production, neurodegeneration, and NFTs formation. This review highlights the involvement of miRNAs in the regulation of APP expression, BACE1 expression and Aβ clearance. Thus, miRNA is possibly used as a treatment tool for AD. In addition to the therapeutic tool, microRNAs are also emerging as diagnostic tools because of their high sensitivity, efficiency, and specificity. It is found in biological fluids like CSF, extracellular fluid, pleural fluid, seminal fluid, bronchial secretions, breastmilk, serum, blood, plasma, etc. Thus, given the intricacy of AD development, illness history, and diagnosis, future treatment methods such as miRNA and anti-miRNA (antimiR, antagonir) techniques are needed:

i. It will be coupled with improvements in the development of sensitive and precise neuroimaging and biofluid-based diagnostic tools for miRNA and other AD-relevant biomarkers,

ii. It will need to be simultaneous and multimodal, addressing numerous disease pathways, and neurological symptoms to block basic illness progression while minimizing ancillary off-target consequences,

iii. It will be used for screening in conjunction with basic medical care and as a second level diagnostic work-up for expert diagnosis and clinical treatment,

iv. It may entail correct medication therapy and distinct therapeutic development within the neurophysiological perspectives and the systems biology.

Conflict of interest

The authors declare no conflict of interest.

Abbreviations

3′UTR 3′-untranslated region
AChE acetylcholinesterase
ACID APP intracellular domain
AD Alzheimer’s disease
ADAM10 a disintegrin and metalloproteinase 10
Ago argonaute protein
AKT protein kinase B
APP amyloid precursor protein
Aβ amyloid beta
BACE1 β-site amyloid precursor protein cleaving enzyme 1
BDMs blood-derived monocytes
C83 proteolytic products of APP
CCL2/CCR2 chemokine (c-c motif) ligand 2/chemokine (c-c) receptor type 2
CREB1 CAMP responsive element binding protein 1
CSF cerebrospinal fluid
DGCR8 DiGeorge syndrome critical region 8
DLG4 discs large homolog 4
DPYSL2 dihydropyrimidinase-related protein 2
<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drosha</td>
<td>ribonuclease III enzyme</td>
</tr>
<tr>
<td>DUSP6</td>
<td>dual specificity phosphatase 6</td>
</tr>
<tr>
<td>EFNA3</td>
<td>ephrin A3</td>
</tr>
<tr>
<td>Evs</td>
<td>extracellular vesicles</td>
</tr>
<tr>
<td>FDG</td>
<td>fluorodeoxyglucose</td>
</tr>
<tr>
<td>FTD</td>
<td>frontotemporal disorder</td>
</tr>
<tr>
<td>GRIA1</td>
<td>glutamate receptor 1</td>
</tr>
<tr>
<td>GRIN2B</td>
<td>glutamate receptor ionotropic, NMDA 2B</td>
</tr>
<tr>
<td>GSK-3β</td>
<td>glycogen synthase kinase-3β</td>
</tr>
<tr>
<td>hATTR</td>
<td>hereditary transthyretin-mediated amyloidosis</td>
</tr>
<tr>
<td>HCC</td>
<td>healthy cognitive controls</td>
</tr>
<tr>
<td>HEK293</td>
<td>human embryonic kidney cell-line</td>
</tr>
<tr>
<td>Ho-1</td>
<td>heme oxygenase 1</td>
</tr>
<tr>
<td>IGF1</td>
<td>insulin-like growth factor 1</td>
</tr>
<tr>
<td>MAPK</td>
<td>mitogen-activated protein kinases</td>
</tr>
<tr>
<td>MCI</td>
<td>mild cognition impairment</td>
</tr>
<tr>
<td>MEF2D</td>
<td>myocyte-specific enhancer factor 2D</td>
</tr>
<tr>
<td>MME (NEP)</td>
<td>membrane metalloendopeptidase (neutral endopeptidase)</td>
</tr>
<tr>
<td>MMSE</td>
<td>mini-mental state examination</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>mTOR</td>
<td>mammalian target of rapamycin</td>
</tr>
<tr>
<td>N2a</td>
<td>neuro-2-a cell</td>
</tr>
<tr>
<td>NF-κB</td>
<td>nuclear factor kappa beta</td>
</tr>
<tr>
<td>NFTs</td>
<td>neurofibrillary tangles</td>
</tr>
<tr>
<td>NGS</td>
<td>next-generation sequencing</td>
</tr>
<tr>
<td>Nrf2</td>
<td>nuclear factor erythroid 2-related factor 2</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PPAR</td>
<td>peroxisome proliferator-activated receptor gamma</td>
</tr>
<tr>
<td>PPP1CA</td>
<td>PP1-alpha catalytic subunit gene</td>
</tr>
<tr>
<td>pri-miRNAs</td>
<td>primary miRNAs</td>
</tr>
<tr>
<td>PTEN</td>
<td>phosphatase and tensin homolog</td>
</tr>
<tr>
<td>RARA</td>
<td>retinoic acid receptor alpha</td>
</tr>
<tr>
<td>RISC</td>
<td>RNA-induced silencing complex</td>
</tr>
<tr>
<td>ROCK1</td>
<td>Rho-associated, coiled-coil-containing protein kinase 1</td>
</tr>
<tr>
<td>SAD</td>
<td>sporadic Alzheimer’s disease</td>
</tr>
<tr>
<td>SAMP8</td>
<td>senescence-accelerated mouse prone</td>
</tr>
<tr>
<td>sAPP</td>
<td>soluble amyloid precursor protein</td>
</tr>
<tr>
<td>SH-SY5Y</td>
<td>human derived neuroblastoma cell line</td>
</tr>
<tr>
<td>siRNA</td>
<td>small interfering RNAs</td>
</tr>
<tr>
<td>SIRT1</td>
<td>silent mating type information regulation 2 homolog</td>
</tr>
<tr>
<td>STIM2</td>
<td>stromal interaction molecule 2</td>
</tr>
<tr>
<td>SYN2</td>
<td>synapsin II</td>
</tr>
<tr>
<td>SYT1</td>
<td>synaptotagmin-1</td>
</tr>
<tr>
<td>TMOD2</td>
<td>tropomodulin 2</td>
</tr>
<tr>
<td>TNFAIP1</td>
<td>TNF alpha induce protein 1</td>
</tr>
<tr>
<td>VAMP2</td>
<td>vesicle-associated membrane protein 2</td>
</tr>
</tbody>
</table>
Author details

Heena Chauhan¹, Pawan Gupta² and Bhagawati Saxena¹∗

¹ Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, India

² Department of Pharmacology, Shree SK Patel College of Pharmaceutical Education and Research, Ganpat University, Mehsana, India

∗Address all correspondence to: bsaxenapharm@gmail.com; bhagawati.saxena@nirmauni.ac.in

IntechOpen

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References


[33] Hébert SS, Horré K, Nicolaï L, Bergmans B, Papadopoulou AS,


Alzheimer’s Disease


[51] Zhao Y, Jaber V, Lukiw WJ. Over-expressed pathogenic miRNAs in Alzheimer’s disease (AD) and prion disease (PrD) drive deficits in TREM2-mediated Aβ42 peptide clearance. Frontiers in Aging Neuroscience. 2016;8:140


MicroRNAs as Future Treatment Tools and Diagnostic Biomarkers in Alzheimer's Disease
DOI: http://dx.doi.org/10.5772/intechopen.103173


[67] Li J, Wang H. miR-15b reduces amyloid-β accumulation in SH-SY5Y cell line through targeting NF-κB signaling and BACE1. Bioscience Reports. 2018;38(6):BSR20180051


Medicine and Cellular Longevity. 2021;2021:8844455


[77] Norris DR, Clark MS, Shipley S. The mental status examination. American Family Physician. 2016;94(8):635-641


MicroRNAs as Future Treatment Tools and Diagnostic Biomarkers in Alzheimer’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.103173


[118] Sarkar S, Engler-Chiurazzi E, Cavendish J, Povrozni J, Russell A,


Abstract

Alzheimer’s Disease (AD), a common type of dementia, characterized by the presence of aggregated extracellular amyloid-beta (Aβ), intracellular hyper phosphorylation of tau protein and neurodegenerative with cognitive decline. It is projected that 141 million people will be suffering with AD by 2050 but no effective drug treatment is discovered without side effects. There is an urgent need for the application of alternative and non-pharmacological interventions for AD. Sporadically found that exercise or diet therapy or social activity may positively influence the AD. In this review we discussed the process of how Exercise-Eating pattern and Social inclusion (EES) has been shown to have fewer side effects and better adherence with AD. In this mechanism the EES can modulate the brain metabolic factors, brain-derived neurotrophic, ketone bodies, lactate, cathepsin-B, irisin, hormonal balance in AD. This review also described the potential biological mechanisms underlying exercise (modulation of biomolecule turnover, antioxidant and anti inflammation), eating pattern (bioactive compounds) and social inclusion that is very important to ameliorate the pathophysiological hallmarks of Alzheimer’s disease. Thus, this EES can be an effective approach to manage the neurodegenerative disorder as well as Alzheimer’s disease.

Keywords: Exercise-eating pattern and social inclusion (EES), neuromodulators, metabolic factors, pathophysiological-hallmarks, new approach to AD

1. Introduction

Alzheimer’s disease (AD) is a form of dementia, currently affecting over 55 million people worldwide. This alarming situation is projected to the elevation of 88 million people by 2050 [1, 2]. It is a complex mechanism of neurodegenerative disorder clinically categorized by advanced and continuing deterioration in intellectual capability of the brain and biochemical change due to the presence of neurotic threads, specific areas of the brain function damage subsequently synaptic signal loss. This consequence occurs due to the accumulation of specific protein amyloid-β to the external neurons and modification of the specific tau protein by hyper phosphorylation and ultimately
neurofibrillary twists (NFTs) are formed in the neuron cell of the brain. This mechanism is responsible to intellectual deficit, remembrance loss, and then neuron expiry [3, 4]. AD is one of the pathetic disease eases due to the presence of disability in the oldest people and it was found that the prevalence of AD is less than 1% in the people who are underneath 60 years of age, but this prevalence is increasing to 40% among people who are older than 85 [5]. The most important thing is that, there is no specific drug for the treatment of AD to date [4]. The alarming disease burden is concerned in the world, because the projected global population of older adults (defined as those aged >60 year) in the year of 2050 will be 2 billion (approximately 21% of the world’s population) out of them 392 million will be over 80 years of old [6]. Presently preventive measures are getting more attention than pharmacological interventions after unsuccessful clinical trials of some promising drugs designed for targeting Aβ and tau proteins. Though, there is no specific treatment of the AD but world scientists are trying to control the gradual growth of AD by multidomain non pharmaceutical intervention such as exercise or diet, and intellectual or physical activity that can prevent cognitive decline at-risk of the oldest population [7]. There is no available information about together-intervention of exercise with diet pattern and social inclusion to ameliorate the prevalence of AD. This is a very important and socially demanding strategy of mass elder people rather than pharmacological intervention.

2. Pathological hallmarks of AD

Two most important determinants in or out of the neuron cells in the brain that are involved in the mechanism of dementia progression, i.e., the β-amyloid peptide and tau proteins. The pathophysiological change of AD is normally carried out by measuring the deposition of β-amyloid peptide, a 39–43 amino acid chain that is produced in the brain and organized a flame-shaped neurofibrillary tangles of tau protein in the affected region of the brain [3]. In patient of AD, one of the determinant (β-amyloid peptide) in the brain is found abnormal due to the genetic mutations in the gene of precursor protein of β-amyloid peptide and Presenilins (PS1 and PS2) which lead to anomalous Aβ accumulation outside the neuron in the brain [4]. Another important determinant tau protein treats the microtubule gathering and maintenance due to the hyperphosphorylation of tau protein and is the cause of AD pathology, The actually mechanism of abnormal microtubule gathering is hyper phosphorylation of tau protein because the modified tau protein can accelerate the formation of neurofibrillary tangles (NFTs), that is associated with loss of remembrance and wisdom hearts [8]. The microtubule disassembly (neurofibrillary tangles; NFTs) may likewise found in other distinctive neurodegenerative diseases, have some distinguishing morphological change rather than AD and this is due to a distinctive conformation of tau isoforms that could easily differentiate from AD [9]. On the other hand, the degree of dementia was observed to be weakly correlated with the amounts and distribution of Aβ deposition within the brain [10]. In particular, the increased deposition of Aβ peptide outside the neuron cell can cause abnormal synaptic signal transduction, intellectual linkage, mitochondrial energy transduction, apoptosis of neuronal cell and, ultimately remembrance forfeiture, the hallmark of AD [11, 12]. Even though some neurotoxicity occurs in the neuronal cell, the mechanism of neurotoxicity caused by Aβ is not fully discovered. Although some studies showed that the abnormal accumulation of Aβ peptide in the brain causes induction of oxidative stress and neuroinflammation, the most important cause of neurotoxicity [13]. Early detection of the determinants is one the most important parameters for the management of AD. But the aforementioned two determinants are very difficult to early determination. Thus defective metabolism of glucose in the brain may be
one of the earliest hallmarks of AD. The detection of brain glucose hypometabolism is measured by the determination of fluoro-2-deoxy-D-glucose positron emission tomography imaging system. This technique has been suggested as an effective early diagnostic tool for AD. Several studies showed the sensitivity and effectiveness of the brain glucose hypometabolism technique (about 90%) for the early diagnosis of AD [14]. Moreover, amino acids may be another hallmark of AD. For instance, abnormal elevation of homocysteine (Hcy) in the AD population. Studies showed that hyperhomocysteinemia is accompanied with amplified intellectual deterioration in healthy older adults with a higher risk of perceptive deficiency [15]. Another study found that abnormal plasma homocysteine and distressed homocysteine amino acid metabolism are risk factors for intellectual concept [5]. Several potential mechanisms have been studied on the harmful effects of homocysteine amino acid in the brain including oxidative deterioration [16], cerebrovascular impairment [17], DNA destruction [18], and activation of N-methyl-D-aspartate receptors [19]. In the Figure 1, we summarized the various modifiable risk determinants that are responsible for AD pathology.

3. Mechanisms involved for the development of AD

The Aβ peptide (approximate size ~4 kDa) is resulting by cleavage of the larger β-amyloid precursor protein (AβPP). β- and γ-secretase are the two membrane-bound endoprotease activities sequentially cleaved the AβPP to produce (Figure 2) the most abundant fragment Aβ40 (~80 to 90%) and Aβ42 (~5 to 10%). The somewhat extensive forms of Aβ, predominantly Aβ42, is the principal culprit for the deposition in the brain [20]. The enzyme, β-Secretase is a protease which have two major homologous (~65%) forms, one is β-site Amyloid Precursor Protein Cleaving Enzyme (BACE1) and the other is BACE2. The most important Enzyme BACE1
is mainly accountable for β-amyloid peptide production higher in the brain than BACE2 which is mostly present in the peripheral tissues. Animal studies stated that the protease BACE1 is the foremost β-secretase action in the brain, however, some residual motion might be attributable by the BACE2. Besides the brain, The BACE1 are also found in another cell type such as pancreatic β-cells where they are highly expressed in mRNA levels, however, this pancreatic isoform of BACE1 is distinctive from the brain and may not cleave AβPP. It was found that BACE1 action upsurges with oldness and is highly found (two to five-fold) in irregular AD [21, 22]. It is important that the lack of protease activity of BACE1 is related to prevent β-amyloid peptide synthesis [23]. Recent studies also observed that in a suitable situation cathepsin B or cathepsin D may help to serve such kind of enzyme like β-secretase enzymes. The two enzymes, β- and γ-secretase were considered to be the leading goals for the advance of anti-AD medications [24]. For example, alterations in γ-secretase activity by the change of allosteric γ-secretase controlling representatives may prevent the production of β-amyloid peptide [25]. Study showed a reduction in BACE1 expression that is related to glucose metabolism via regulation of insulin mRNA expression. In vivo experiments stated that reduction of BACE1 expression may lower plasma insulin concentrations and body weight through the controlling of regular glucose acceptance and insulin sensitivity [26].

Another relationship of AD has also been exposed to be concomitant with inflammation, glucose metabolism and hormonal balance. For instance, the inflammatory markers have been isolated in the cerebrospinal fluid (CSF) and abnormal amyloid formation found in the brain of AD that is much related to high expression of inflammatory molecules interleukin-6 (IL-6). This relationship is not only found in the brain but also in the other fluid such as the lumbar and ventricular region in patients with AD. Another relationship was found that circulating IL-6 is highly expressed before symptomatic sign of dementia and this increased IL-6 is related with low male hormone like testosterone in older men with type-II diabetes Mellitus (T2DM) and AD [27–29]. It was found that male hormone secretion is hampered by inflammatory molecules IL-6 and this is much
related to inflammation and oxidative stress, hormonal imbalance and T2DM with AD pathology [30–31]. Figure 2 summarized the amyloidogenic pathway involved for development of AD [32–35].

4. Mechanisms involved for the prevention of AD

The prevention of AD means the degradation of β-amyloid peptides by enzymes such as Aβ degrading enzyme Neprilysin (NEP) and insulin degrading enzyme (IDE). There are many enzymes, the aforementioned two important enzymes are metalloprotease which are responsible for most of the Aβ degradation [36, 37]. The membrane bound Neprilysin is actually type II metalloprotease which degrades the extracellular variety of peptides but the IDE enzyme can degrade both intra- and extracellular [38]. Though the affinity of IDE enzyme to the insulin is (twenty times higher) higher than Aβ but it hydrolyzes slowly. It is important that the insulin may be responsible for cleavage of β-amyloid peptides, this is the basic mechanism among type II diabetes, hyperinsulinemia, and AD [39, 40]. Most of the Aβ degradation occurs by the influence of NEP, like lysosomal degradation of cathepsin B [41]. Another study stated that other enzymes such as Endothelin Converting Enzyme (ECE), Angiotensin- Converting Enzyme (ACE), and Matrix Metalloproteinase-9 (MMP-9) may also have Aβ degrading properties [42]. Though the substantial degradation of β-amyloid peptides occurs in the brain, their undegraded portion is transported through the blood brain barrier (BBB) into the circulation by specific mechanisms. The soluble part of β-amyloid peptide is switched through the BBB into the abluminal site of the brain by the low-density lipoprotein receptor-related protein (LRP) and into the luminal side of the blood by the receptor for advanced glycation end products (RAGE) [43, 44]. Disturbing this mechanism may cause an increase of Aβ level which may be attached with other widespread co-morbid vascular irregularities in the brain function of AD. This change may exaggerate the development of amyloid pathology [45]. Figure 3 summarized the detailed preventive mechanism of AD by Aβ degradation pathway. The frequency of AD is found meaningfully higher in women than to men (almost two-thirds) indicating a strong association of sex hormones with the AD [46]. Study observed that testosterone levels are inversely associated with the plasma levels of β-amyloid peptides in elderly men population [47]. Testosterone may provide different neuroprotective effects including enlightening intellectual presentation and synaptic signal transduction by increasing relaxation, modulation synapse density level on the brain hippocampal dendritic spines [48, 49]. This hormone is also important for maintaining hippocampal function in elderly population [50], increasing blood supply to the cerebral and increasing glucose metabolism in the responsive brain regions as well as reduced the aggregation of β-amyloid peptides and neurotoxicity. Testosterone may reducing the tau protein hyperphosphorylation and in vivo experiment showed that the reduction of testosterone is directly associated with reduce intellectual performance, and it could be revised by testosterone supplementation [51, 52]. Women are more prone to AD than men because testosterone is basically a male hormone and most abundant testosterone is converted into estrogen and other adrenal hormones in women. The study showed that women are more prone to AD symptoms due to lack of testosterone [53]. Previous animal study indicated that testosterone (in male) and estrogen (in female) could modulate the invention of β-amyloid peptides by the disturbing of BACE1 action [54, 55]. The hormone like testosterone is an effective modulator of endogenous β-amyloid peptides degrading enzymes such as NEP. Animal study observed that neuronal expression of NEP is enhanced by the action of testosterone which in turn reduces the β-amyloid peptide level and ultimately reduces the symptoms of AD [56]. The increase of β-amyloid peptides degrading enzymes positively
influence on the level of toxicity or fibrillization of amylin [57, 58]. Testosterone may regulate the enzymes NEP and IDE and improve the AD conditions [53]. Another protein, the APOE ε4 allele is very related to the AD, promoting β-amyloid peptides clearance, and it was found that the isoform ApoE ε2 and ApoE ε3 are very efficient than the ApoE ε4 protein. The modification among the isoform may influence the ability of ApoE to promote β-amyloid peptides degradation, and the modification of ApoE is subjected by its lipid carrier molecule ABCA1, whereby higher modification may increases the clearance of β-amyloid peptides [59, 60]. The insulin impairment and the brain function are associated with AD [53]. Brain insulin is very special and mostly originated from endogenous production which is not influenced by the plasma insulin [61]. The mechanism of insulin action in the brain describes the signal transduction via signal cascade pathway. In which first insulin binds to the insulin receptors and then phosphorylation occurs on multiple substrates such as insulin receptor substrate-1 and insulin receptor substrate-II. This phosphorylated substrate activates the downstream signaling pathways and activates the phosphatidylinositol 3-kinase, which is an important modulator for synaptic malleability, education, and remembrance. The activation of phosphatidylinositol 3-kinase subsequently activates Akt which phosphorylates enzymes related to glucose metabolism such as glycogen synthase kinase (GSK) 3β. Then GSK3β regulates tau protein phosphorylation in AD, and thereby leading to neurofibrillary tangle formation [62, 63]. In vitro and in vivo studies demonstrated that impairment of insulin signaling pathway is associated with the AD pathology [64–66]. There is a strong linkage among the hormone testosterone, insulin and glucose metabolism through glucose transporter and insulin receptor protein [67]. Studies have shown that testosterone influence the glucose uptake and transporter via activation of liver kinase B1/AMP-activated protein kinase signaling pathway in fat cell, where AMPK plays an important role for decreasing mTOR signaling activity and promotes lysosomal degradation of β-amyloid peptides in AD. However, this mechanism can also lead to β-amyloid peptides generation and tau phosphorylation [68, 69]. Several studies have shown that both precursor protein (APP) and β-amyloid peptides co-localize

![Figure 3. Preventive mechanism of AD by Aβ degradation pathway.](image-url)
in mitochondria, suggesting the possibility of mitochondrial function is associated with APP biology [70]. Ketone bodies may block the mitochondrial amyloid entry and improve understanding capability [71]. This ability would predictably ameliorate Aβ-mediated suppression of respiratory chain function and perhaps could rescue the bioenergetics hypo metabolism that is observed in AD brains [72]. Alternatively, improving mitochondrial performance outright could reduce the production of Aβ and increase the production of soluble APPα [73].

5. Dietary pattern for the prevention and treatment of Alzheimer disease

Dietary patterns which are rich in antioxidant and anti-inflammatory properties, may involve the establishment of auspicious attitudes in the treatment of intellectual deterioration or suspending the development of dementia in the brain [74]. The bio ingredient of diet can change the epigenetic by regulating deoxyribonucleic acid (DNA) modification such as methylation, acetylation, histone protein modifications, and changes of gene expression in the ribonucleic acid (RNA) level. The epigenetic modification may influence the expression of particular genes and subsequently particular marker molecules that are responsible for epigenetic alterations [75]. Lipidation of several molecules are important for brain function, one of them are polyunsaturated fatty acids (PUFAs) [76]. The PUFA are the important component of neuronal cell membranes, which is responsible for membrane fluidity. The crossing of molecules through the membrane allows them for cell signaling and neuronal protection [77]. The essential PUFAs play not only neuroprotection but also involve development and brain functions. They also have antioxidant, anti-excitotoxic, and anti-inflammatory activities in the brain. Imbalance of PUFA has been found in neuropsychiatric health including dementia. The beneficial effects of long-chain omega-3 PUFAs have been observed in populations where long-chain omega-3 PUFAs effectively reduce the risk of cerebral damage in individuals without dementia. This is supported by other studies in such a way that omega-3 fatty acid may effectively reduce the initial stages of intellectual deterioration [78]. Another dietary bioactive compound, curcumin (turmeric powder), plays an important role against β-amyloid peptides deposition in the AD because they have potent antioxidant, anti-inflammatory, and neuroprotective function [79]. The bioactive compound, curcumin, regulates the genetic control by down regulation of several gene expression such as class I HDACs (HDAC1, HDAC3, and HDAC8) and enhances the acetylation of histone H4 levels. The curcumin regulates not only gene expression but also can inhibit certain epigenetic enzymes [80]. Other dietary bioactive compounds, flavonoids have potent antioxidant properties, can modulate epigenetic control by the down regulation of pro-inflammatory and inflammatory cytokines and prevent neural impairment in AD [81, 82]. Thus, flavonoids could be a promising therapeutic intervention against neurodegenerative disease. In vivo and in vitro studies showed that the bioactive compound quercetin may regulates cytokines via activation of several downstream molecules such as nuclear factor (Nrf2), Paraoxonase-2, c-Jun N-terminal kinase (c-JNK), Protein kinase C (PKC), Mitogen-activated protein kinase (MAPK) signaling cascades, and PI3K/Akt pathways [83]. Dietary source of component such as cocoa and seed coat of the black soybean, rich source of plant flavonoids and anthocyanin respectively, have been shown neuroprotective action against intellectual deterioration, oxidative stress, neurodegeneration, and memory impairment in a mouse model of AD via the PI3K/Akt/Nrf2/HO-1 pathways [84, 85]. The dietary patterns of coffee and tea that contain bioactive caffeine have been shown to reverse intellectual impairment and reduce the β-amyloid peptides aggregation in the brain in mice model of AD. This
reduction occurs due to the stimulation of protein kinase A activity by the caffeine and increases the phospho-CREB levels, subsequently reducing the phospho-JNK and phosphor-ERK expression in the brain. Thus, the high level of blood caffeine may inhibit the progression to dementia \[86, 87\]. Dietary pattern of grapes and red wine that contains resveratrol, a polyphenol of potent antioxidant and anti-inflammatory actions \[88\]. The reactive oxygen species (ROS) induced oxidative stress is protected by the resveratrol by the activation of sirtuin 1 (SIRT1) \[89\]. Resveratrol also activates a transcriptional coactivator of energy metabolism and several studies have shown that resveratrol supplementation with vitamin D could prevent intellectual impairment in vivo through Amyloidogenic pathways \[90, 91\]. Another study stated that resveratrol may ameliorate the hippocampal neurodegeneration and memory performance \[92\]. Insufficient dietary minerals may adversely affect the critical cellular processes associated with intellectual impairment and dementia. Thus, dietary patterns of sufficient minerals may have a protective role against many metabolic diseases including intellectual deterioration \[93, 94\]. Compelling evidence shows that magnesium deficiency may impair memory and contributes to AD pathology \[95\]. Magnesium sufficient dietary patterns may modify AβPP processing and stimulate the α-secretase cleavage pathway, thereby protecting the cognitive dysfunction \[96\].

Dietary patterns of vitamin rich food might be useful in maintaining intellectual function and delaying the progression of AD. Studies have stated that vitamin rich dietary patterns such as folic acid and vitamin B12 can significantly improve intellectual functions \[97\]. In AD, oxidative stress and mitochondrial dysfunction can be prevented by vitamins, because vitamin can modulate the oxidative stress

**Figure 4.**
*Mechanism of how dietary patterns are involved for the treatment of AD.*
markers and misfolded proteins [98, 99]. Clinical studies suggested that ketogenic therapies may be beneficial for AD patients. It was found that plasma ketone levels were increased by the medium chain triglyceride and ketone ester supplementations and improved the intellectual function in AD patients [100]. Another source of fuel for the brain is ketone bodies (KB), which may provide energy for the brain and also increase mitochondrial efficiency and cognitive function. The two forms of KB are very important for these mechanisms in the brain; beta-hydroxybutyrate (b-HB) and acetoacetate. Evidence suggests that brain ketone body utilization is not problematic in AD like glucose, making it an alternative energy source of brain function [101]. Figure 4 summarized the dietary management of AD.

6. The mechanism of how exercise-eating patterns can modulate the brain function of AD

In the brain of an AD patient, there are several mechanisms for the changes of β-amyloid peptides synthesis and degradation and tau protein modification. Physical activity may change many signaling molecules both at the mRNA and protein level that may induce the anatomical changes of the brain, chemical and electrophysiological change of the nerve, subsequently enhance the plasticity of neurons of the brain and improve the brain function. Multiple paths of physical exercise and dietary pattern are likely enabled to adjust the level of β-amyloid peptides and tau protein directly or indirectly. Both physical activity and habituated dietary healthy food are effective interventions in such a way that can limit the prevalence of neurodegenerative diseases through the minimization of mitochondrial dysfunction in bioenergetics processes [102, 103]. Physical exercise play an important role on neuroplasticity of the brain and cellular energy homeostasis well as improve the cognitive functions by controlling the activation of several signaling molecules such as PGC-1α and a nicotinamide adenine dinucleotide (NAD)- dependent deacetylase, SIRT1 [104, 105]. There is a loss of muscle mass and muscle activity with elderly people. Thus, regular exercise and a healthy dietary pattern reduces the development of aging-related muscle deterioration and promotes muscle activity with the older people [106]. Few have shown the the efficacy of exercise with men and women in AD people, even though differences were found in men and women cognitive improvement with exercise. Study showed that exercise can modulate insulin action and as well as blood glucose [107]. In vivo and clinical study have shown the benefit of exercise and dietary pattern as a non-pharmalogical option in reducing the β-amyloid peptides aggregation and tau protein phosphorylation in the aging brain. This mechanism happens less in women rather than men due to the change of hormone level [108]. In vivo study stated that exercise and healthy dietary patterns can reduce cortical BACE1 expression and activity by modulating the MAPK signaling in the cortex in AD patients [109].

Interestingly, animal and human studies have shown that exercise and specific dietary patterns may increase testosterone production but it is depending on the intensity of exercise and exercise-induced testosterone sustained for a long time in the body. It was found that high intensity of exercise can increase testosterone levels in T2DM patients, which is important for the reduction of risk factors of AD [110].

The most important neurotrophins, BDNF (brain-derived neurotrophic factor) is responsible for neurogenesis and synaptogenesis. Not only can the central nervous system (CNS) produce the BDNF but also skeletal muscle through the exercise. The underlying molecular mechanisms of exercise to produce testosterone may be mediated by BDNF production in the brain. Physical exercise may increase testosterone. Thus, exercise and dietary patterns may increase BDNF levels as a stimulus for the
induction of neurogenesis to improve synaptic plasticity [111, 112]. Together physical exercise and dietary patterns not only increase the BDNF but also increase the insulin like growth factor-I (IGF-I). The mechanism of exercise and dietary pattern have been shown to enhance IGF-1 expression in the brain [113]. Moreover, exercise may release several factors like BDNF and IGF-1 into the circulation by testosterone activation. Neurocognitive damage is lifelong incidence with cellular dysfunction. For instance, impairment of BDNF production may influence the synaptic plasticity and neurogenesis in the aging adult brain [114, 115]. Exercise as well as dietary patterns such as low-calorie intake is another important intervention for enlightening metabolic health. The molecular mechanism of low-calorie intake (LCI) is effective against ROS induced-oxidative stress, in which the LCI can reduce β-amyloid peptides aggregation and γ-secretase and plays a preventive role in AD pathology [116, 117]. It was found that the mechanism of low-calorie intake exerts its action by inhibiting nutrient-sensing and inflammatory pathways, thus physical activity and dietary pattern may also be effective methods for the preventive measures of AD [118]. The cellular energy homeostasis is mediated by AMPK in mitochondria, adipose tissue, skeletal muscle, and liver. This mechanism is activated by LKB1 and in response to metabolic stresses, exercise, sex hormones, and insulin sensitizing agents such as Metformin. Thus, the physical exercise and healthy dietary pattern plays a key role in AD patients [119–121]. Oxidative stress and inflammation are the hallmarks of dementia. Individuals’ cognitive abilities are related to both non-modifiable factors and modifiable risk factors such as exercise and dietary status. Low calorie diet may be effective against cognitive decline and the high calorie is Vice versa [122]. Additionally, some dietary patterns that contain bioactive compounds

Figure 5. Mechanism of exercise mediated management of AD.
may increase signaling molecules and neuronal hormones that are responsible for cognitive improvement. Diet therapy such as vitamin rich food may affect the bodies’ central metabolism as well as brain function, and the production of neurotransmitters for modulation of mood in AD [123, 124]. Conversely, it was found that lack of basic B complex (folic acid, B6, and B12) in the dietary pattern is also proposed to impact on the rate of brain atrophy associated with mild cognitive impairment (MCI) [125]. Strength exercise and other dietary patterns such as intake of seafood and other sources of long-chain omega-3 polyunsaturated fats (LC-n3-FA) may have long-term beneficial effects on cognitive function [126, 127]. Thus, exercise and dietary patterns may balance several factors such as LC-n3-FA act via BDNF, and insulin-like growth factor-1 (IGF-1) can alter the expression of a number of protein pathways in neuronal function, plasticity, and neurogenesis [128]. Figure 5 summarized the exercise and dietary management of AD.

7. Social inclusion for the treatment of AD

Social inclusion is multidimensional including social and cultural connection with family, friends, work, personal interests and local community, deal with personal crisis etc., and operates at various social levels. In AD, the deterioration of brain activity begins in the hippocampus areas primarily associated with memory and emotion. The deterioration then spreads to other regions, resulting in reduced neuronal processing, eventually associated with episodic memory, emotion and mood, sensation, self-awareness, attention, memory retrieval and theory of mind which is adversely affected in the early stages of AD. Thus, it could be suggested that the brain regions affected by AD may share something in common, including their role of regulating emotion, memory and awareness and social inclusion can significantly affect in a broad range of measures, including a reduction of cognitive decline, reduction in perceived stress, increase in quality of life, as well as increases in functional connectivity, percent volume brain change and cerebral blood flow in areas of the cortex [129–131]. For the treatment of AD, Social inclusion is potentially beneficial in improving the cognitive function of older adults with mild to moderate dementia and improving their quality of life. Thus, it is recognized as a priority field of AD research, as pharmacologic treatments have not demonstrated effective outcomes [132]. Social inclusion may promote communication and enhance social interaction skills that are important for potentially beneficial cognitive functions and domains of memory and recall of older adults with dementia. These non-pharmacological interventions aim to reduce the behavioral symptoms of the AD. For instance, music therapy involves listening to music and singing songs, can modulate the factors involved in cognition and conduct, divert the attention of older adults to provoke emotional responses and modulate them, draw on different cognitive functions, and evoke movement patterns. Another study has indicated that singing traditional songs, which emerged from the life experiences of people living with dementia, activates their implicit memory with a priming effect [133]. Traditional opera can potentially be an effective therapy for improving the cognitive function of older adults with dementia, reducing their behavioral and psychiatric symptoms and enhancing their quality of life [134]. Moreover, it helps improve their memory as well as the coherence and expressiveness of their speech [135]. About ninety percent people with dementia showed behavioral and psychological symptoms and can cause serious complications but reduction of this complication by use of single antipsychotic medications is very difficult. Several studies showed that consideration of both the physical and the social inclusion can promote self-determination and opportunities for meaning and purpose of persons...
Alzheimer's Disease

with dementia [136]. Recent studies concluded that the level of evidence is considered insufficient to support the use of single non pharmacological interventions in prevention efforts of AD; however, mega study reported that around one third of ADs cases worldwide might be attributable to potentially modifiable risk factors such as smoking, physical inactivity, and midlife obesity [137].

8. Conclusion

Single nonpharmacological interventions for the treatment of pathophysiological hallmarks of AD was not sufficient. It should include a new approach of three effector modulations such as exercise–eating pattern and social (EES) activities for the treatment of AD. However, when considering the single modulator exercise, adapting the physical environment is necessary but not sufficient. To effectively address AD, the exercise and eating pattern must also be incorporated into the intervention. Also, when considering social inclusion related to initiatives aimed at decreasing AD, providing initial training is necessary, ongoing training and support to mindfulness, meditation in the form of effective enabling and reinforcing factors must also be included. Finally, development of individualized approaches that promote self-control exercise, eating patterns and social inclusion of persons with dementia. This new approach EES should also be included with other interventions aimed at decreasing AD. Though it is very important that the combination of EES and other interventions would be supportive by the success of interventions. It is our hope that this new approach EES also provides direction for future research and initiatives aimed at successful and sustainable nonpharmacological management of AD.

Acknowledgements

I am particularly grateful Jashore University of Science and Technology for the logistic support of this review article.

Author details

Afroza Sultana and Md Alauddin*
Department of Nutrition and Food Technology, Jashore University of Science and Technology, Bangladesh

*Address all correspondence to: mdalauddin_nft@just.edu.bd

IntechOpen

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References


[2] Yaghoubi A. The Effects of Aerobic Training and Omega-3 Intake on Aβ42, Neprilysin, and γ- Secretase in the Hippocampus of Male Rats Alzheimer’s model. Tehran, Iran: Islamic Azad University; 2021. DOI: 10.21203/rs.3.rs-427829/v1


Alzheimer's Disease


[24] Schechter I, Ziv E. Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional beta-secretase candidate(s). Biological Chemistry. 2008;389:313-320


[34] Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ. The intracellular domain of the beta-amylloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. The Journal of Biological Chemistry. 2001;276:40288-40292


[38] Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiology of Aging. 2006;27:190-198


Alzheimer’s Disease


[51] Rosario ER, Carroll J, Pike CJ. Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Research. 2010;1359:281-290

[52] Papalia MA, Davis SR. What is the rationale for androgen therapy for women? Treatments in Endocrinology. 2003;2:77-84


[61] Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM. Insulin in the brain: Its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and


Perspective Chapter: Exercise-Eating Pattern and Social Inclusion (EES) is an Effective...
DOI: http://dx.doi.org/10.5772/intechopen.101611


Alzheimer’s Disease

Sciences of the USA. 2007;104:12017-12022. DOI: 10.1073/pnas. 0705070104


Perspective Chapter: Exercise-Eating Pattern and Social Inclusion (EES) is an Effective...
DOI: http://dx.doi.org/10.5772/intechopen.101611


[136] Caspar S, Davis ED, Douziech A, Scott DR. Nonpharmacological management of behavioral and psychological symptoms of dementia:

This Edited Volume *Alzheimer’s Disease* is a collection of reviewed and relevant research chapters, offering a comprehensive overview of recent developments in the field. The book comprises single chapters authored by various researchers and edited by an expert in the field, working on Alzheimer’s disease and dementia with cutting-edge technology. All chapters are complete in themselves but united under a common research study topic. This publication aims at providing a thorough overview of the latest research efforts by international authors in this research area, and opening new possible research paths for further novel developments.